var title_f8_32_8704="Brain death criteria by country A";
var content_f8_32_8704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62251%7ENEURO%2F70736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62251%7ENEURO%2F70736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for  brain death by country: 2001 International Survey data",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Continent/country",
"      </td>",
"      <td class=\"subtitle1\">",
"       Apnea test",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of physicians",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observation time, h",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ancillary test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       North America",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       United States",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2*",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Canada",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Caribbean",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cuba",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jamaica",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trinidad and Tobago",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Central and South America",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Argentina",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Brazil",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chile",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Columbia",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       2 (N)",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Costa Rica",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       El Salvador",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mexico",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Paraguay",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Uruguay",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Venezuela",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2 (N)",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Europe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Austria",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Belgium",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cyprus",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Czech Republic",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Denmark",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Estonia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Finland",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       France",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Germany",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Greece",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hungary",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       12 (72)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ireland",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Italy",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Luxembourg",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Malta",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Netherlands",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Norway",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Poland",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Portugal",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2-24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Romania",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Russia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCO2: target PCO",
"     <sub>",
"      2",
"     </sub>",
"     defined (50 or 60 mmHg); A: absent criterion or guideline; DVO: disconnection from ventilatory only; N: neurologist.",
"     <br>",
"      * Eight US states only; time within parentheses indicates observation time due to anoxia.",
"      <br>",
"       &bull; Observation time can be shortened or eliminated if one confirmatory test is positive for brain death.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wijdicks, EFM. Brain death worldwide: Accepted fact but no global consensus in diagnostic criteria. Neurology 2002; 58:20. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for  brain death by country: 2001 International Survey data",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Continent/country",
"      </td>",
"      <td class=\"subtitle1\">",
"       Apnea test",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of physicians",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observation time, h",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ancillary test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Europe continued",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slovak Republic",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spain",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sweden",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Switzerland",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6 (48)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Turkey",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ukraine",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       United Kingdom",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Yugoslavia",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Africa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       South Africa",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tanzania",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tunisia",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Middle East",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Iran",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       12, 24, 36",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Israel",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jordan",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lebanon",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Oman",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Qatar",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Saudi Arabia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       24&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       United Arab Emirates",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Asia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bangladesh",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Georgia",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hong Kong",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       India",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Indonesia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Japan",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Korea (South)",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Malaysia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Philippines",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Singapore",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Taiwan",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Thailand",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Oceania",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Australia, New Zealand",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCO2: target PCO",
"     <sub>",
"      2",
"     </sub>",
"     defined (50 or 60 mmHg); A: absent criterion or guideline; DVO: disconnection from ventilatory only; N: neurologist.",
"     <br>",
"      &bull; Observation time can be shortened or eliminated if one confirmatory test is positive for brain death.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wijdicks, EFM. Brain death worldwide: Accepted fact but no global consensus in diagnostic criteria. Neurology 2002; 58:20. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8704=[""].join("\n");
var outline_f8_32_8704=null;
var title_f8_32_8705="Pirenzepine: International drug information";
var content_f8_32_8705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pirenzepine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Droxol (AR);",
"     </li>",
"     <li>",
"      Gastropiron (IT);",
"     </li>",
"     <li>",
"      Gastrozepin (AU, CZ, DE, GR, JP, NL, RU);",
"     </li>",
"     <li>",
"      Gastrozepina (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4152009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Pirenzepine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4288675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4152010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of peptic ulcer",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4152012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years and Adults: Oral: 50 mg twice daily 1 hour before meals; may increase to 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4152013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10518 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-89.32.226.102-BE3A184D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8705=[""].join("\n");
var outline_f8_32_8705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302622\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152009\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288675\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152010\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152012\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821139\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152013\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8706="Cervical agenesis A";
var content_f8_32_8706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66336%7EOBGYN%2F78045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66336%7EOBGYN%2F78045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical agenesis with the presence of a vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical agenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fundus of the uterus is present without the body of the cervix. Dotted lines represent missing cervix and upper vagina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8706=[""].join("\n");
var outline_f8_32_8706=null;
var title_f8_32_8707="Mitral valve prolapse bileaflet four chamber echocardiogram";
var content_f8_32_8707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76601/4chmvpbi_conv.mp4?title=Mitral+valve+prolapse+bileaflet+four+chamber+echocardiogram\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 245px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram shows mild prolapse of both anterior and posterior leaflets of the mitral valve. The leaflets are thickened and show redundancy. The left atrium and ventricle are slightly dilated, suggesting the presence of mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8707=[""].join("\n");
var outline_f8_32_8707=null;
var title_f8_32_8708="Quinagolide: Patient drug information";
var content_f8_32_8708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Quinagolide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/23/42355?source=see_link\">",
"     see \"Quinagolide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4800585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norprolac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some prolactin-secreting tumors.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to quinagolide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11899 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8708=[""].join("\n");
var outline_f8_32_8708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800585\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013034\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013033\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013038\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013039\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013041\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013036\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013037\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013042\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013043\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/23/42355?source=related_link\">",
"      Quinagolide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8709="Renal Bx congenital NS of the Finnish type - tubular changes";
var content_f8_32_8709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Renal Bx congenital NS of the Finnish type - tubular changes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal biopsy from an infant with congenital nephrotic syndrome of the Finnish type due to mutations in the NPSH 1 gene that encodes nephrin, a transmembrane protein located at the slit diaphragm of the glomerular podocytes. The most striking histologic finding is the irregular microcystic dilatation of proximal tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8709=[""].join("\n");
var outline_f8_32_8709=null;
var title_f8_32_8710="Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information";
var content_f8_32_8710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9858?source=see_link\">",
"    see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/36/3654?source=see_link\">",
"    see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14456818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Pentacel&reg; Shortage Dosing Guidelines; Updated",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Center for Disease Control and Prevention (CDC) has issued guidelines for vaccinating children during the Pentacel&reg; and Daptacel&reg; shortage. Sanofi Pasteur expects a shortage of these vaccines to continue through March 2013.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Guidelines may be found on the following CDC website:",
"       <a href=\"file://www.cdc.gov/vaccines/vac-gen/shortages/downloads/pentacel-guidance.pdf\" target=\"_blank\">",
"        file://www.cdc.gov/vaccines/vac-gen/shortages/downloads/pentacel-guidance.pdf",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6215227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pentacel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9748134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediacel&reg;;",
"     </li>",
"     <li>",
"      Pentacel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6215231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial);",
"     </li>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6783449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/36/3654?source=see_link\">",
"      see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     Children 6 weeks to &le;4 years: I.M.: 0.5 mL per dose administered at 2, 4, 6 and 15-18 months of age (total of 4 doses). The first dose may be administered as early as 6 weeks of age. Following completion of the 4-dose series, children should receive a dose of DTaP vaccine at 4-6 years of age (Daptacel&reg; recommended due to same pertussis antigen used in both products).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Per the ACIP, polio vaccine should not be administered more frequently than 4 weeks apart. Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion. Pentacel&reg; is not indicated for the polio booster dose given at 4-6 years of age; Kinrix&reg; or IPV should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Children previously vaccinated with &ge;1 dose of Daptacel&reg; or IPV vaccines: Pentacel&reg; may be used to complete the first 4 doses of the DTaP or IPV series in children scheduled to receive the other components in the vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Children previously vaccinated with &ge;1 dose of",
"     <i>",
"      Haemophilus",
"     </i>",
"     b Conjugate vaccine: Pentacel&reg; may be used to complete the series in children scheduled to receive the other components in the vaccine; however, if different brands of",
"     <i>",
"      Haemophilus",
"     </i>",
"     b Conjugate vaccine are administered to complete the series, 3 primary immunizing doses are needed, followed by a booster dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Completion of 3 doses of Pentacel&reg; provides primary immunization against diphtheria, tetanus,",
"     <i>",
"      H. influenzae",
"     </i>",
"     type B, and poliomyelitis. Completion of the 4-dose series with Pentacel&reg; provides primary immunization against pertussis. It also provides a booster vaccination against diphtheria, tetanus,",
"     <i>",
"      H. influenzae",
"     </i>",
"     type B, and poliomyelitis.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6215235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pentacel&reg;: Diphtheria toxoid 15 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [pertussis toxin detoxified 20 mcg, filamentous hemagglutinin 20 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg], type 1poliovirus 40 D-antigen units; type 2 poliovirus 8 D-antigen units; type 3 poliovirus 32 D-antigen units, and",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 10 mcg [bound to tetanus toxoid 24 mcg] per 0.5 mL (0.5 mL) [contains albumin, aluminum, neomycin, polymyxin B sulfate, and polysorbate 80; supplied in two vials, one containing DTaP-IPV liquid and one containing Hib powder]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6215229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6783454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. administration only. Do not administer I.V. or SubQ. Administer in the anterolateral aspect of thigh in children &lt;1 year of age or deltoid muscle of upper arm in older children. Do not administer to gluteal area or areas near a major nerve trunk. Do not administer additional vaccines or immunoglobulins at the same site or using the same syringe.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends: \"It should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.\" Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6215232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease caused by",
"     <i>",
"      H. influenzae",
"     </i>",
"     type b in children 6 weeks through 4 years of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Advisory Committee on Immunization Practices (ACIP) recommends that Pentacel&reg; (DTaP-IPV/Hib) may be used to provide the recommended DTaP, IPV, and Hib immunization in children &lt;5 years of age. Whenever feasible, the same manufacturer should be used to provide the pertussis component; however, vaccination should not be deferred if a specific brand is not known or is not available. The Hib component in Pentacel&reg; contains a tetanus toxoid conjugate. A Hib vaccine containing the PRP-OMP conjugate (PedvaxHIB&reg;) may provide a more rapid seroconversion following the first dose and may be preferable to use in certain populations (eg, American Indian or Alaska Native children).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8092360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentacel&reg; is supplied in two vials, one containing DTaP-IPV liquid and one containing Hib powder, which must be mixed together in order to administer the recommended vaccine components.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6783403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fussiness/irritability (54% to 77%; &gt;3 hours 4% to 5%), inconsolable crying (36% to 60%; &gt;3 hours &le;2%), lethargy/decreased activity (24% to 46%; severe &le;3%), fever &ge;38&deg;C (6% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Tenderness (39% to 56%; severe 1% to 5%), arm circumference increase &gt;5 mm (34%; &gt;40 mm &lt;1%), redness &gt;5 mm (7% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Local: Injection site reaction: Swelling &gt;5 mm (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis/anaphylactic reaction, apnea, appetite decreased, asthma, bronchiolitis, consciousness decreased, cough, cyanosis, dehydration, diarrhea, encephalopathy, erythema, gastroenteritis, hypersensitivity reactions, hypotonia, hypotonic-hyporesponsive episodes, injection site reactions (abscess, extensive swelling of injected limb, inflammation, mass), pallor, pneumonia, screaming, seizure, skin discoloration, somnolence, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6215233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe allergic reaction to any vaccine containing diphtheria toxoid, tetanus toxoid, pertussis, poliovirus, or",
"     <i>",
"      Haemophilus",
"     </i>",
"     b, or any component of this vaccine; encephalopathy occurring within 7 days of a previous pertussis vaccine not (not attributable to another identifiable cause); progressive neurologic disorders (including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6783398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Apnea: Apnea has been reported following I.M. vaccine administration in premature infants; consider risk versus benefit in infants born prematurely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reactions from previous pertussis vaccine: Carefully consider use in patients with history of any of the following effects from previous administration of a pertussis-containing vaccine: Fever &ge;105&deg;F (40.5&deg;C) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; shock or collapse (hypotonic-hyporesponsive episode [HHE]) occurring within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic disorders: Use with caution in patients with history of seizure disorder, progressive neurologic disease, or conditions predisposing to seizures; ACIP and AAP guidelines recommend deferring immunization until health status can be assessed and condition stabilized. Antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults: Safety and efficacy have not been established in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high-dose corticosteroids); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;6 weeks or &ge;5 years of age. If inadvertently administered to children &ge;5 years as a booster dose, it may be counted as a valid dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Product may contain aluminum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: Product may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polymyxin B: Product may contain polymyxin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Product may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6265257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6783395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6783396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted for this combination product. This product is not indicated for use in women of childbearing age.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13908591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anatetall (MY, TH);",
"     </li>",
"     <li>",
"      Anatoxal TE (PE);",
"     </li>",
"     <li>",
"      TE Anatoxal Berna (CH);",
"     </li>",
"     <li>",
"      Tet-Tox (NZ);",
"     </li>",
"     <li>",
"      Tetanol (AE, AR, AT, BH, CY, DE, EC, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tetatox (BG);",
"     </li>",
"     <li>",
"      Tetavax (HK, MY, NO, PH, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, and",
"      <i>",
"       Haemophilus",
"      </i>",
"      B Conjugate Vaccine and Guidance for Use in Infants and Children,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(39):1079-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/32/8710/abstract-text/18830213/pubmed\" id=\"18830213\" target=\"_blank\">",
"        18830213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(30):829-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/32/8710/abstract-text/19661857/pubmed\" id=\"19661857\" target=\"_blank\">",
"        19661857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/32/8710/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/32/8710/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8980 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8710=[""].join("\n");
var outline_f8_32_8710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456818\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9748134\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215231\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783449\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796198\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796199\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215235\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215229\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783454\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215232\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8092360\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783403\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215233\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783398\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299218\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6265257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783395\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783396\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13908591\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961938\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9858?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/36/3654?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8711="Treatment with digoxin: initial dosing, monitoring, and dose modification";
var content_f8_32_8711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment with digoxin: initial dosing, monitoring, and dose modification",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Lynne Sylvia, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8711/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/32/8711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac glycosides have important positive inotropic, neurohormonal, and electrophysiologic actions, which are the basis for its use in two clinical situations: heart failure due to systolic dysfunction, and in certain supraventricular tachyarrhythmias. The ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    to reduce sympathetic activation has also been recognized. For maximal early benefits, digoxin requires loading doses, which can be administered intravenously or orally.",
"   </p>",
"   <p>",
"    While two cardiac glycosides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and digitoxin) were previously used, digitoxin has not been widely available since the 1980s. As digoxin is now the only cardiac glycoside available in most countries, the method of initiating therapy with digoxin is presented here. Recommendations regarding the use of digoxin in the management of heart failure or arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H17#H17\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Digoxin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrolyte and renal status of each patient should be ascertained prior to initiating treatment and periodically thereafter. Hypokalemia or hypomagnesemia, for example, may promote the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -induced arrhythmias, while impaired renal function may result in higher than anticipated serum drug levels. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dose adjustments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy has been divided into rapid and slow digitalization followed by the maintenance digoxin dose, and the proposed regimens vary considerably. The following principles should be viewed as a general guide to the use of digoxin for its inotropic or electrophysiologic effects, which must be modified according to clinical circumstances. Doses used are smaller and blood levels are lower than those needed for the inotropic effect but are generally sufficient to reduce the sympathetic activation associated with heart failure, the primary mechanism of benefit in heart failure patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2474850\">",
"    <span class=\"h2\">",
"     Rapid digoxin loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid intravenous and oral digitalization is often used to control the ventricular response in atrial fibrillation and flutter. However, other drugs may be more effective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have a more rapid onset of action on the ventricular response in these arrhythmias; therefore, rapid digitalization is rarely needed unless alternative drugs are contraindicated or have not been effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H9#H9\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Pharmacologic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link&amp;anchor=H6#H6\">",
"     \"Control of ventricular rate in atrial flutter\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The total loading dose with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    varies from patient to patient but is usually between 0.75 to 1.5 mg with intravenous administration and 1 to 2 mg with oral administration. (See",
"    <a class=\"local\" href=\"#H12454686\">",
"     'Dose adjustment in renal disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2161313\">",
"     'Dose adjustment in patients of low body weight'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2161430\">",
"    <span class=\"h3\">",
"     Intravenous loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most rapid means of digitalization is the intravenous route. An initial intravenous dose of 0.25 to 0.5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is given over several minutes, followed by 0.25 mg every 6 hours for a total loading dose of 0.75 to 1.5 mg. Intravenous digoxin begins to act in 15 to 30 minutes with a peak effect in 1 to 5 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2161437\">",
"    <span class=\"h3\">",
"     Oral loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid oral digitalization can be accomplished by giving 0.5 mg initially followed by 0.25 mg every six hours for a total loading dose of 0.75 to 1.5 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2474877\">",
"    <span class=\"h2\">",
"     Slow digoxin loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow oral digitalization can be achieved by starting a maintenance dose of 0.125 to 0.25 mg daily. A steady state will be achieved after five cycles of the drug half-life",
"    <span class=\"nowrap\">",
"     (T1/2&szlig;),",
"    </span>",
"    which is approximately 7 to 10 days in the average subject.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12454599\">",
"    <span class=\"h2\">",
"     Maintenance digoxin dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients, the maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    will be between 0.125 mg and 0.25 mg daily. The proper daily maintenance dose can be estimated from the product of the total effective loading dose times the percent daily loss. The latter can be estimated from one of the following formulas, where PCr is the plasma creatinine concentration (in",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and CCr is the creatinine clearance (in",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Percent daily loss in men = 11.6 + [20 &divide; PCr]",
"     </li>",
"     <li>",
"      Percent daily loss in women = 12.6 + [16 &divide; PCr]",
"     </li>",
"     <li>",
"      Percent daily loss = 14 + [CCr &divide; 5]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, in a subject with normal renal function, the loading dose will be about 1 mg (70 percent of which is bioavailable), and the percent daily loss is about 35 percent. Thus, the maintenance dose will be about 0.25 mg.",
"   </p>",
"   <p>",
"    However, significant variation in maintenance doses is common and is dependent on many factors, including renal function and concomitant medication use. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dose adjustments'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MONITORING SERUM DIGOXIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12105027\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relatively narrow therapeutic window of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , with substantial overlap between so-called therapeutic and toxic levels, patients taking digoxin require monitoring of the serum digoxin concentration, with the \"optimal\" level varying with the clinical setting. Monitoring the serum digoxin level is particularly important in persons with chronic renal dysfunction or rapidly changing renal function, as significantly decreased renal function can lead to accumulation of digoxin and its metabolites and predispose to digoxin toxicity. Additionally, patients with electrolyte disturbances, particularly hypokalemia and hypomagnesemia, which may be related to diuretic therapy or other medications, are at increased risk for digoxin-associated arrhythmias and should undergo monitoring of the serum digoxin level until serum potassium level and magnesium concentration return to the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dose adjustments'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link&amp;anchor=H3#H3\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\", section on 'Plasma digoxin levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration is most important when digoxin is used in the treatment of heart failure with systolic dysfunction, whereas levels are only checked when used in patients with atrial fibrillation if toxicity is suspected. Blood samples should be obtained at least 6 hours, but optimally 12 hours, after administration of digoxin to ensure completion of distribution from the blood to the tissues. In patients with advanced kidney disease or who are on hemodialysis, the digoxin level should be checked at least 12 to 24 hours after the prior dose. Serum digoxin concentrations measured prior to these times may be falsely elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2161374\">",
"    <span class=\"h2\">",
"     Adjusting the digoxin dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assuming that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    level was drawn at the correct time, at steady state, and under conditions of stable renal function, there is a linear relationship between digoxin dose and serum concentration. As an example, a steady state concentration is measured and returns at 1.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (2.05",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in a patient taking a daily maintenance dose (for this example, 0.25 mg daily). Assuming the desired serum concentration is 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    the dose should be reduced by 50 percent (to 0.125 mg daily in this example). The same linear relationship is true for patients whose serum concentration is lower than desired in whom a dose increase is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is used in the treatment of heart failure, the serum digoxin level should be measured 7 to 10 days after starting digoxin or changing the dose of digoxin, at which point a steady state should have been achieved. For patients with heart failure, the target serum digoxin level for maximal efficacy and minimal risk of toxicity is between 0.5 and 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.65 to 1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    for maximal efficacy with minimal risk of toxicity (",
"    <a class=\"graphic graphic_figure graphicRef80620 \" href=\"UTD.htm?24/42/25262\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/4\">",
"     4",
"    </a>",
"    ]. Higher serum levels should be avoided since they are associated with an increased risk of toxicity without clear evidence of enhanced efficacy. If the patient is subsequently stable, monitoring is repeated every 3 to 6 months or when there is a change in clinical status or toxicity is suspected.",
"   </p>",
"   <p>",
"    Clinical trials in patients with normal sinus rhythm that demonstrated benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy have targeted mean serum digoxin concentrations ranging from 0.5 to 1.75",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.65 to 2.25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The doses used to achieve these values ranged from 0.125 to 0.5 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/5\">",
"     5",
"    </a>",
"    ]. Post hoc analyses from the DIG trial demonstrated improved outcomes in patients with serum digoxin levels of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.65 to 1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. In contrast, higher serum levels were associated with increased mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link&amp;anchor=H11#H11\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\", section on 'Optimal digoxin level'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is generally less effective for rate control of atrial fibrillation (AF) than beta blockers or calcium channel blockers, is less likely to control the ventricular rate during exercise (when vagal tone is low and sympathetic tone is high), has little or no ability to terminate the arrhythmia, and often does not slow the heart rate with recurrent AF. Thus, large doses of digoxin are often required for monotherapy, and patients frequently require the addition of a beta blocker or calcium channel blocker for optimal rate control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is used strictly for ventricular rate control in AF, serum digoxin levels should be monitored periodically, although the drug concentration often does not correlate with ventricular rate control and is used more as a guide to toxicity than to therapy. Junctional escape beats (as detected by the equality of all the longest observed R-R intervals on the electrocardiogram) are common when digitalis has successfully slowed the ventricular rate. Giving more digoxin in this setting will increase the degree of AV nodal block and produce periods of regular junctional rhythm. The change from single junctional escapes to periodic junctional rhythm usually signifies the development of digoxin toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H7983933#H7983933\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Effect of high degrees of AV nodal block and exit block on ventricular response'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link&amp;anchor=H24718286#H24718286\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\", section on 'Junctional rhythm, tachycardia, and bradycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relation to digoxin toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sympatholytic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    may occur at serum drug concentrations less than those used to produce an inotropic effect. As an example, one study found that increasing the digoxin dose from a mean of 0.2 to 0.39",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (corresponding to an increase in serum concentrations from 0.67 to 1.22",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [0.85 to 1.55",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    increased ejection fraction; however, there was no increase in exercise tolerance or decrease in venous norepinephrine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    -related cardiac arrhythmias and extracardiac symptoms can occur when the serum digoxin concentration is in the therapeutic or even subtherapeutic range; as a result, the presence of digoxin toxicity or excess is often a",
"    <strong>",
"     clinical diagnosis",
"    </strong>",
"    irrespective of circulating levels (unless of course the value is zero). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DOSE ADJUSTMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bioavailability is between 70 and 80 percent for conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    tablets and between 75 and 85 percent for digoxin elixir, and the",
"    <span class=\"nowrap\">",
"     T1/2&szlig;",
"    </span>",
"    of digoxin ranges from 33 to 50 hours when renal function is normal (",
"    <a class=\"graphic graphic_table graphicRef60113 \" href=\"UTD.htm?28/6/28779\">",
"     table 1",
"    </a>",
"    ). Unlike certain other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ), the bioavailability of the oral dose forms of digoxin does not appear to be affected by heart failure. Dose adjustments of digoxin are necessary in patients with renal dysfunction, patients with low body weight, and with the concomitant use of certain medications. The effect of digoxin in patients with heart failure and the need for dose adjustments in such patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12454686\">",
"    <span class=\"h2\">",
"     Dose adjustment in renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 to 80 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is eliminated unchanged in the urine, leading to prolongation of the half-life in patients with renal insufficiency. Renal insufficiency also decreases the extravascular volume of distribution of digoxin, another effect that can elevate plasma drug levels. As a result,",
"    <strong>",
"     both the initial loading dose and the maintenance dose must be reduced in patients with underlying renal disease. In end-stage renal disease, for example, the loading dose should be one-half to two-thirds normal.",
"    </strong>",
"   </p>",
"   <p>",
"    The maintenance dose in patients with impaired renal function is again estimated using the following formulas, where PCr is the plasma creatinine concentration (in",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and CCr is the creatinine clearance (in",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Percent daily loss in men = 11.6 + [20 &divide; PCr]",
"     </li>",
"     <li>",
"      Percent daily loss in women = 12.6 + [16 &divide; PCr]",
"     </li>",
"     <li>",
"      Percent daily loss = 14 + [CCr &divide; 5]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this example, the daily loss is only about 17 percent when the plasma creatinine concentration is 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (352",
"    <span class=\"nowrap\">",
"     &micro;mol/L);",
"    </span>",
"    as a result, the daily maintenance dose will be reduced by one-half.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12454715\">",
"    <span class=\"h2\">",
"     Dose adjustment with hepatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic disease has little influence on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    metabolism or clearance; therefore, no dose adjustment is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30785637\">",
"    <span class=\"h2\">",
"     Dose adjustment in patients who are obese",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with normal weight subjects, neither volume of distribution nor clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    are consistently altered by changes in body composition associated with obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Therefore, standard (non-weight based) loading and maintenance doses should be used. If a weight based dose is used, Ideal Body Weight is suggested (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2161313\">",
"    <span class=\"h2\">",
"     Dose adjustment in patients of low body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with body weight of less than 45 kg should receive 50 percent of the normal loading and maintenance doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12454767\">",
"    <span class=\"h2\">",
"     Dose adjustment with concomitant medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of important drug interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can increase serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      levels. With concurrent quinidine administration, for example, the digoxin dose should be reduced by one-half [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/14-17\">",
"       14-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      and antacids, on the other hand, can decrease the intestinal absorption of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      by 20 to 35 percent, necessitating an increase in the daily dose. To avoid these interactions, digoxin should be dosed one hour before or two to three hours after the administration of the antacids or cholestyramine.",
"     </li>",
"     <li>",
"      Diuretics may increase digitalis toxicity as a result of a decrease in the glomerular filtration rate and the development of electrolyte abnormalities, especially hypokalemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      can interfere with the sequential hydrolysis pathway of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      metabolism (which begins in the stomach and is responsible for less than 15 percent of the metabolism in most patients but which can be significantly more active in a minority of patients). As such, these drugs increase digoxin levels in approximately 10 percent of patients in whom this pathway is a significant component of the drug's metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12454742\">",
"    <span class=\"h2\">",
"     Digoxin in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    crosses the placenta and has been used for both fetal and maternal cardiac indications without report of fetal harm or teratogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8711/abstract/18\">",
"     18",
"    </a>",
"    ]. As such, there is no contraindication for using digoxin during pregnancy or during lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2474884\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac glycosides such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      have important positive inotropic, neurohormonal, and electrophysiologic actions which are the basis for its use in two clinical situations: heart failure due to systolic dysfunction, and in certain supraventricular tachyarrhythmias, primarily atrial fibrillation (AF) and atrial flutter. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid intravenous and oral digitalization is used to control the ventricular response in AF and atrial flutter (see",
"      <a class=\"local\" href=\"#H2474850\">",
"       'Rapid digoxin loading'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial intravenous doses of 0.25 to 0.5 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      are given over several minutes, followed by 0.25 mg every six hours for a total dose of 1 mg.",
"     </li>",
"     <li>",
"      Rapid oral digitalization can be accomplished by giving 0.5 mg initially followed by 0.25 mg every six hours for a total loading dose of 1 mg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slow oral loading of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      can be achieved by starting a maintenance dose of 0.125 to 0.25 mg daily, which results in a steady state serum level of drug in approximately 7 to 10 days in the average subject. (See",
"      <a class=\"local\" href=\"#H2474877\">",
"       'Slow digoxin loading'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the relatively narrow therapeutic window of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , with substantial overlap between so-called therapeutic and toxic levels, patients taking digoxin require monitoring of the serum digoxin concentration, with the \"optimal\" level varying with the clinical setting. Monitoring the serum digoxin level is particularly important in persons with chronic renal dysfunction, rapidly changing renal function, or electrolyte disturbances (eg, hypokalemia, hypomagnesemia). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Monitoring serum digoxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assuming that the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      level was drawn at the correct time, at steady state, and under conditions of stable renal function, there is a linear relationship between digoxin dose and serum concentration which should be followed for any necessary dose adjustments. (See",
"      <a class=\"local\" href=\"#H2161374\">",
"       'Adjusting the digoxin dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is used in the treatment of heart failure, the serum digoxin level should be measured 7 to 10 days after starting digoxin or changing the dose of digoxin, at which point a steady state should have been achieved. For patients with heart failure, we suggest maintaining digoxin levels between 0.5 and 0.8",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (0.65 to 1",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      for maximal efficacy with minimal risk of toxicity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is used strictly for ventricular rate control in AF, serum digoxin levels should be monitored periodically, although the drug concentration often does not correlate with ventricular rate control and is used more as a guide to toxicity than to therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 70 to 80 percent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is eliminated unchanged in the urine, leading to prolongation of the half-life in patients with renal insufficiency. Renal insufficiency also decreases the extravascular volume of distribution of digoxin, another effect that can elevate plasma drug levels. As a result, both the initial loading dose and the maintenance dose must be reduced in patients with underlying renal disease. (See",
"      <a class=\"local\" href=\"#H12454686\">",
"       'Dose adjustment in renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can increase serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      levels, thereby requiring a reduction in the daily digoxin dose.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      and antacids, on the other hand, can decrease the intestinal absorption of digoxin, necessitating spacing of the doses or an increase in the daily digoxin dose. In some patients, use of antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      may impair gastrointestinal metabolism of digoxin, leading to higher serum digoxin concentrations. (See",
"      <a class=\"local\" href=\"#H12454767\">",
"       'Dose adjustment with concomitant medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/1\">",
"      Jelliffe RW. An improved method of digoxin therapy. Ann Intern Med 1968; 69:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/2\">",
"      Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/3\">",
"      Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/4\">",
"      Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/5\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/6\">",
"      Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/7\">",
"      Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988; 259:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/8\">",
"      Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/9\">",
"      Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/10\">",
"      Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995; 92:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/11\">",
"      Ewy GA, Groves BM, Ball MF, et al. Digoxin metabolism in obesity. Circulation 1971; 44:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/12\">",
"      Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986; 11:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/13\">",
"      Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/14\">",
"      Leahey EB Jr, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA 1978; 240:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/15\">",
"      Doering W. Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med 1979; 301:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/16\">",
"      Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine interaction Pharmacokinetic evaluation. N Engl J Med 1979; 300:1238.",
"     </a>",
"    </li>",
"    <li>",
"     Roden D. Quinidine. In: Electrophysiology and Pharmacology of the Heart, Dangman KH, Miura DS (Eds), Marcel Dekker, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8711/abstract/18\">",
"      Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1051 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8711=[""].join("\n");
var outline_f8_32_8711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2474884\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2474850\">",
"      Rapid digoxin loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2161430\">",
"      - Intravenous loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2161437\">",
"      - Oral loading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2474877\">",
"      Slow digoxin loading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12454599\">",
"      Maintenance digoxin dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MONITORING SERUM DIGOXIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12105027\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2161374\">",
"      Adjusting the digoxin dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relation to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DOSE ADJUSTMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12454686\">",
"      Dose adjustment in renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12454715\">",
"      Dose adjustment with hepatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30785637\">",
"      Dose adjustment in patients who are obese",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2161313\">",
"      Dose adjustment in patients of low body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12454767\">",
"      Dose adjustment with concomitant medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12454742\">",
"      Digoxin in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2474884\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1051|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/42/25262\" title=\"figure 1\">",
"      Digoxin level and survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/6/28779\" title=\"table 1\">",
"      Digitalis kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=related_link\" title=\"calculator 2\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=related_link\">",
"      Control of ventricular rate in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8712="Differential diagnosis of peripheral nerve and muscle disease";
var content_f8_32_8712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of peripheral nerve and muscle disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8712/contributors\">",
"     Seward B Rutkove, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8712/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8712/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/32/8712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, the diagnosis of peripheral nerve and muscle disease can be made from the clinical setting. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of diabetic polyneuropathy in a patient with long-standing diabetes mellitus who presents with classic \"stocking-glove\" sensory loss is relatively straightforward. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"       \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reasonable clinical hypothesis can be formed regarding the etiology of proximal weakness in patients taking drugs that can interfere with muscle function (eg, antimalarial, glucocorticoid, or cholesterol lowering medications). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, patients with disorders of nerves, muscle, or the neuromuscular junction can present with a similar constellation of symptoms. In addition, even when the process is localized to the nerve, it is not always clear if the origin of the problem is in the central or peripheral nervous system.",
"   </p>",
"   <p>",
"    This topic will review the findings on history and physical examination that are characteristic of diseases of the nerve, muscle, and neuromuscular junction, and then present an approach to distinguishing central from peripheral neurologic disease. Specific neurologic syndromes are discussed in more detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL DISTINCTION BETWEEN NERVE, MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases of the nerve (eg, polyneuropathy), muscle (eg, myopathy), and neuromuscular junction (eg, myasthenia gravis) may present with varying degrees of sensory loss and weakness. Nevertheless, specific patterns of the sensory and motor disturbance may help differentiate between these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal sensory loss in the absence of a known central nervous system (CNS) lesion suggests a peripheral problem occurring somewhere along the length of the nerve between the nerve root and the most distal fibers. Identifying the distribution of sensory loss is paramount and is discussed in further detail below. The loss of certain modalities (eg, vibration or",
"    <span class=\"nowrap\">",
"     sharp/dull",
"    </span>",
"    discrimination) may also help identify the problem.",
"   </p>",
"   <p>",
"    Weakness can arise from dysfunction of nerve, neuromuscular junction, or muscle. Weakness tends to be a difficult symptom for patients to quantify and localize. Frequently patients will complain of pain and associated weakness. However, since pain may limit the action and mobility of a joint, the finding of weakness in the setting of pain may not indicate true neurologic dysfunction. Patients who complain of painless weakness generally have significant abnormalities on examination. Similar to sensory loss, the distribution of weakness is extremely important. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Motor'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cranial nerve complaints can be very useful in localizing the site of the problem. In the absence of CNS disease, diplopia is likely secondary to a neuromuscular junction defect. Progressive dysarthria without associated eye symptoms suggests motor neuron disease (eg, amyotrophic lateral sclerosis). Less frequently, myopathies or acute motor polyneuropathies (such as Guillain-Barr&eacute; syndrome) can present with dysarthria and eye movement abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination should focus upon the distribution of muscle weakness and sensory loss and the deep tendon reflexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Motor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of muscle weakness is an important distinguishing feature. Proximal weakness is most consistent with a myopathy or neuromuscular junction disorder. Weakness in these individuals is usually symmetric, with involvement of head extensors and flexors, although mild asymmetries are not unusual. However, some patients with myasthenia may present with or develop predominately distal weakness. Repetitive movements may increase the weakness in myasthenia gravis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the weakness involves predominantly only one extremity, it is useful to determine if the lesion is in the distribution of a single root, a region of the plexus, or a single nerve territory; this requires a detailed knowledge of the anatomy. The examination can be confounded if multiple lesions are superimposed in a single limb, eg, a simultaneous radiculopathy plus a focal mononeuropathy, or multiple mononeuropathies.",
"   </p>",
"   <p>",
"    Observation of the muscles themselves is often helpful. Important features include the presence of fasciculations, whether the muscle produces a painful cramp after activation, and the presence of atrophy. Such findings may occur in amyotrophic lateral sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sensory",
"    </span>",
"    &nbsp;&mdash;&nbsp;In axonal polyneuropathies, \"glove and stocking\" sensory loss is most prominent, initially affecting the feet and later the hands (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    ). Root lesions may cause sensory loss in a dermatomal pattern. Numbness in a single nerve territory might suggest an entrapment neuropathy. Multiple areas of numbness in different extremities point to a mononeuropathy multiplex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of reflexes suggests a neuropathic lesion, generally affecting either sensory or motor fibers. Globally depressed or absent reflexes are frequently associated with Guillain-Barr&eacute; syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    ). Reflexes are generally preserved in muscle disease unless it is severe. Neuromuscular junction disorders do not follow a clear pattern: in myasthenia gravis reflexes are generally normal; in Lambert-Eaton myasthenic syndrome, reflexes are reduced or absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Additional signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulbar and ocular signs suggest CNS disease, but if fluctuating or slowly progressive may point to a neuromuscular problem. Patients with myasthenia gravis, if presenting with limb weakness, will usually have a degree of diplopia and fatigable ptosis on examination of the extraocular muscles. Atrophy and fasciculations of the tongue may suggest ALS.",
"   </p>",
"   <p>",
"    Checking the Tinel test, that is, tapping over a nerve to test for reproduction of pain and paresthesia (",
"    <a class=\"graphic graphic_picture graphicRef58010 \" href=\"UTD.htm?31/20/32064\">",
"     picture 1",
"    </a>",
"    ), might be helpful. A patient with intermittent numbness of the leg and a markedly positive Tinel sign over the fibular neck may have a peroneal neuropathy. However, the sensitivity and specificity of this test is generally low (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\", section on 'Provocative maneuvers'",
"    </a>",
"    ). Multiple Tinel signs can be present in patients with polyneuropathy; in one study the sensitivity and specificity of this finding was 79 and 42 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8712/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin findings may be subtle but can help identify the source of the problem. Distal hair loss over the feet is common in patients with polyneuropathy. A healing, painful dermatomal rash may point to a recent episode of herpes zoster (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    ). Unusual color changes with pain can point to complex regional pain syndrome accompanying a peripheral nerve lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Points of confusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some presenting symptoms may be difficult to interpret.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain is generally not a prominent symptom of myopathy. Most myopathic processes are relatively painless, including polymyositis, dermatomyositis, toxic myopathies, and inclusion body myositis. Generally, muscle pain is confined to patients with acute rhabdomyolysis, a few metabolic myopathies (such as McArdle Disease), and myopathies associated with connective tissue disease (the pain perhaps secondary to joint involvement rather than muscle involvement itself).",
"     </li>",
"     <li>",
"      Myopathies may be superimposed upon polyneuropathies. As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      can produce a severe myopathy, usually associated with a polyneuropathy. Patients with connective tissue diseases may also have both polyneuropathy and myopathy. In a critically ill patient who develops flaccid generalized weakness, the major considerations in the differential diagnosis are critical illness myopathy and critical illness polyneuropathy, or a combination of the two. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link\">",
"       \"Neuromuscular weakness related to critical illness\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Contrary to standard teaching, proximal weakness is sometimes caused by nerve problems and distal weakness by myopathy. As an example, patients with Guillain-Barr&eacute; syndrome occasionally present with proximal weakness secondary to predominant polyradiculopathy. On the other hand, some myopathies such as inclusion body myositis or myotonic dystrophy may cause significant distal weakness that is greater than proximal weakness.",
"     </li>",
"     <li>",
"      Mononeuropathy multiplex, when longstanding, can produce signs and symptoms suggestive of a polyneuropathy. The multiple mononeuropathies produce confluent sensory loss and weakness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"       \"Overview of polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISTINGUISHING PERIPHERAL FROM CENTRAL NERVOUS SYSTEM DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases of the peripheral nervous system include the mononeuropathies, polyneuropathies, and mononeuropathy multiplex, each of which may be caused by a variety of underlying systemic illnesses, toxic exposures, and rheumatic genetic diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distinguishing peripheral from CNS disease (eg, that due to stroke, brain tumor, or spinal cord lesions) is straightforward in most cases. Weakness or sensory loss confined to one limb generally suggests a peripheral nerve problem. If there is associated pain in the extremity, then the likelihood of a peripheral process is even greater.",
"   </p>",
"   <p>",
"    However, localization of the problem is less clear when weakness or sensory loss is no longer confined to one limb or when no associated",
"    <span class=\"nowrap\">",
"     pain/discomfort",
"    </span>",
"    is present. A patient who presents with painless sensory loss and numbness in the feet may have a polyneuropathy or a spinal cord lesion. Complaints of poor coordination or unsteady gait can also represent primarily central or peripheral dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important clues regarding the origin of nervous system complaints can be derived from asking detailed questions about pain, the time course of illness, and central nervous system dysfunction. Both central and peripheral nervous system disorders can be present simultaneously; in such a situation, even detailed questioning of a patient may not clarify the origin of the problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, extremity pain in addition to neurologic complaints is suggestive of a peripheral nervous system process. However, the presence of pain can be misleading. A number of CNS disorders, including spinal cord lesions, can be accompanied by varying types of pain. In a study of 127 patients with pain of likely spinal cord origin, steady pain was present in 95 percent of cases, intermittent (often shooting) in 31 percent, and evoked (such as allodynia or hyperpathia) in 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8712/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with strokes can also experience extremity pain, particularly if the stroke was localized to the brainstem or thalamus. In most of these instances the pain affects the arm and leg on one side.",
"   </p>",
"   <p>",
"    Pain can originate from outside the nervous system, for example due to an arthritic joint. These patients may also complain of weakness secondary to the pain induced by movement of the joint or limb.",
"   </p>",
"   <p>",
"    Pain that is position-dependent or brought on with activity (such as calf or thigh pain with walking in patients with spinal stenosis) is more likely of peripheral than central origin. In addition, pain that radiates into a very discrete area is unlikely to be central. However, random or diurnal fluctuations in pain are common in many peripheral and central disorders and may not help with localization of the problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute onset of weakness or sensory loss in an awake, alert patient who is not performing an activity or maintaining an unusual posture is likely to be central in origin, while symptoms that come on after maintaining one position for a prolonged time are probably peripheral in origin. Examples of the latter include hand paresthesias while driving in a patient with carpal tunnel syndrome, and penile numbness after prolonged bicycling (secondary to compression of the pudendal nerve in the perineum). Disorders that develop over days or weeks, and those with onset during sleep, are more difficult to classify.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other central nervous system disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms suggesting other CNS disease support a central origin of symptoms. Questions aimed at identifying central dysfunction may include whether the patient is experiencing any cognitive difficulties or subtle problems in additional extremities, subtle vision loss, nausea, vomiting, or headaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination plays an important role in differentiating central and peripheral nervous system disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8712/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the deep tendon reflexes is the single most important test in determining whether a problem is peripheral or central. Brisk reflexes, especially if associated with a \"pathologic\" sign, such as the Babinski reflex or Hoffman's sign, suggest central pathology. Hyporeflexia or areflexia points to a peripheral problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Motor examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation of the muscles may yield useful information before examining strength. Atrophy of muscles isolated to a specific root(s) or peripheral nerve places the problem in the peripheral nervous system. Mild disuse atrophy occurs in patients with motor lesions of the CNS, but severe reduction in muscle bulk is not typically observed with central lesions alone. Fasciculations suggest a peripheral process.",
"   </p>",
"   <p>",
"    Increased tone on passive movement of the extremities suggests a CNS process. Side to side comparison is helpful in distinguishing subtle abnormalities. Normal or decreased tone is found in most peripheral processes.",
"   </p>",
"   <p>",
"    Weakness caused by upper motor neuron (CNS) problems generally follows a specific pattern. Following a motor stroke, for example, extensor muscles in the arm (deltoid, triceps, wrist, and finger extensors) and flexor muscles in the leg (iliopsoas, hamstrings, and foot dorsiflexors) are weakest. Hemiplegia is straightforward to localize, but a patient with an incomplete spinal cord lesion who has only unilateral leg weakness may prove a greater diagnostic challenge.",
"   </p>",
"   <p>",
"    Weakness caused by radiculopathy, plexopathy, or nerve entrapments is usually restricted to only a specific group of muscles. Rarely, however, a patient with a stroke may present with relatively isolated weakness, perhaps of just the hand.",
"   </p>",
"   <p>",
"    Peripheral problems that cause generalized weakness often affect the neck extensor muscles prominently. As examples, myasthenia gravis, amyotrophic lateral sclerosis, and Guillain-Barr&eacute; syndrome can all produce marked neck extensor weakness. This pattern is very atypical in most central disorders.",
"   </p>",
"   <p>",
"    Symmetric generalized weakness is more likely peripheral than central, and may suggest myopathy or diffuse polyneuropathy, although cervical myelopathy or brainstem lesions can also cause generalized weakness. Symmetric proximal weakness involving both the arms and legs is usually associated with myopathy or neuromuscular junction disease and is unlikely to be central in etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sensory examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory loss that follows a specific nerve or root territory and can be brought on by position changes is suggestive of a peripheral process. Examples include numbness in the fingers with wrist flexion (Phalen maneuver) in patients with carpal tunnel syndrome or sensory loss over the lateral thigh with standing in patients with meralgia paresthetica.",
"   </p>",
"   <p>",
"    Determining which sensory modalities are most affected is useful. A peripheral problem is more likely when all modalities are affected to some extent, although peripheral processes may also present with predominant loss of only one or two modalities (eg, reduced pain and temperature sensation in patients with a polyneuropathy affecting small unmyelinated fibers). Some central processes, such as syringomyelia, also may present with one or two modalities affected, such as reduced pain and temperature sensation and preserved light touch in the arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Coordination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal coordination without associated weakness suggests a central problem. A central process should also be considered if coordination is affected out of proportion to weakness. However, some patients with weakness due to peripheral nerve disease may have some degree of incoordination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gait",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many central disorders are accompanied by changes in gait, such as the festinating gait of a patient with Parkinson disease, the hemiplegic gait of a patient with a stroke, or the \"frontal\" gait in a patient with normal pressure hydrocephalus. Gait disorders are often idiopathic or multifactorial in origin, especially in the elderly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9417?source=see_link\">",
"     \"Gait disorders of elderly patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral disorders also occasionally have stereotypical gait abnormalities. A steppage gait, where the patient needs to lift the knees up high to overcome weakness in foot dorsiflexors, can be seen in patients with polyneuropathy such as Charcot-Marie-Tooth disease. A waddling gait is characteristic of patients with proximal muscle weakness, as with myopathy. An antalgic gait occurs when posture and walking are altered in order to avoid or reduce pain. It arises from musculoskeletal rather than neurologic problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cranial nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many generalized neuromuscular diseases affect the cranial nerves to some extent. Mild degrees of facial or bulbar weakness can be present in myopathies and neuromuscular junction disorders. Similar findings, including eye movement abnormalities, can be identified in patients with polyradiculoneuropathy (such as Guillain-Barr&eacute; syndrome).",
"   </p>",
"   <p>",
"    Cranial nerve signs are often subtle (especially when symmetric), and may manifest themselves mainly as overactivation of the frontalis muscle, mild ptosis, or subtle eye movement abnormalities or nasality to the voice. Examination of the tongue for atrophy and fasciculations is also important, especially when considering the diagnosis of motor neuron disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other important distinctions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of situations may present diagnostic dilemmas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory loss that begins in the feet and moves proximally is usually caused by polyneuropathy, but it also can be a sign of a spinal cord lesion. The simplest way of differentiating the two is by examination of tone and reflexes; increased tone and hyperreflexia would point to a central process.",
"     </li>",
"     <li>",
"      Patients who develop the acute onset of painless unilateral hand and finger extension weakness may present a diagnostic dilemma. This pattern is typical of the distribution of upper motor neuron problems, although an acute radial neuropathy can produce identical signs. In radial neuropathy, however, the brachioradialis usually is also weak, a muscle not typically affected in stroke. Thus, examining the strength of this muscle (and its bulk during contraction compared with the normal side), can help make the distinction between these two entities. The brachioradialis flexes the elbow with the hand midway between pronation and supination and during contraction can be palpated radially in the proximal forearm.",
"     </li>",
"     <li>",
"      Localizing the origin of a bladder problem based upon the history and examination can be difficult. Urgency and incontinence generally suggest upper motor neuron dysfunction. Patients with bladder difficulties from lower motor neuron problems typically present with weak streams and overflow incontinence. Distinguishing between these complaints can be challenging since many patients simply note an increased frequency of urination. Urodynamic studies may be useful when bladder difficulties are the predominant complaint. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"       \"Clinical presentation and diagnosis of urinary incontinence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fatigue is a nonspecific complaint that may be hard to sort out. It is important to clarify what the patient means by fatigue, as many individuals use fatigue as a synonym for \"sleepy.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Generalized fatigue is usually not a symptom of peripheral nervous system disease, although it may be a sequela of polio (ie, post-polio syndrome) and Guillain-Barr&eacute; syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8712/abstract/5\">",
"       5",
"      </a>",
"      ]. In post-polio syndrome, progressive weakness, pain, and fatigue ensue decades after the episode of poliomyelitis. The mechanism for fatigue in both of these peripheral disorders is uncertain.",
"     </li>",
"     <li>",
"      Weakness, not fatigue per se, tends to be the hallmark of most neuromuscular junction and muscle diseases.",
"     </li>",
"     <li>",
"      Many patients with CNS demyelination, as in multiple sclerosis, complain of fatigue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with moderate or severe peripheral nervous system disease, a superimposed central process can be very difficult to identify. This was illustrated in a patient with diabetes mellitus and polyneuropathy who presented with progressive leg weakness, fever, and absent reflexes in the lower extremities, leading a clinician to suspect an acute polyneuropathy. After a prolonged evaluation, a thoracic epidural abscess producing a myelopathy was finally identified. A Babinski sign was absent due to atrophy of leg muscles and loss of sensory nerve fibers from chronic diabetic polyneuropathy. This suggests that when the end-organs are not working normally, a central process cannot be excluded by examination.",
"   </p>",
"   <p>",
"    Even the most experienced neurologist may have difficulty correctly identifying a problem as peripheral or central. In most acute situations, it is more important to exclude a possible central process, since substantial neurologic recovery in the CNS is unlikely. As an example, excluding stroke is more important than eliminating a radial neuropathy in patients with hand weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of diagnostic tests are available to augment the history and physical examination in distinguishing between neurologic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography and nerve conduction studies are the two most common diagnostic tests for establishing a diagnosis of nerve and muscle disease after the history and examination. It is often worth performing these tests prior to ordering additional blood tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrodiagnostic studies are tailored for patients individually; the clinician should carefully consider what they are looking for when referring a patient for these tests. The electromyographer should be given some background information, although too much data (eg, results of radiologic studies) may bias the examiner. Similarly, the referring physician should avoid narrowing the question too much; in a patient with proximal arm pain and hand numbness, asking to rule out only carpal tunnel syndrome may cause the electromyographer to miss a plexopathy or radiculopathy. The electromyographer typically performs a history and physical examination which can help tailor the study. Referral to a neurologist or neuromuscular specialist before performing",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    is useful in particularly complex or confusing cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superimposed processes may make interpretation of the",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    difficult. As an example, underlying diabetic neuropathy can complicate the diagnosis in a patient with radiculopathy.",
"   </p>",
"   <p>",
"    Many technical factors also play a role in the accuracy and legitimacy of a study.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conduction velocity will slow and response amplitude will increase if the patient's limbs are cool. Thus, a patient may be inadvertently diagnosed with carpal tunnel syndrome if the hand is cool.",
"     </li>",
"     <li>",
"      Normal values for nerve conduction studies are not firmly established in older populations; some variability in interpretation is inevitable in this population.",
"     </li>",
"     <li>",
"      Obesity may make certain tests more difficult to perform. Electrical interference or other",
"      <span class=\"nowrap\">",
"       hardware/software",
"      </span>",
"      problems can also interfere with results.",
"     </li>",
"     <li>",
"      Needle examination is safe in anticoagulated patients given the small size of the needles typically used. Nevertheless, EMG of the paraspinal muscles is usually not performed in these individuals to avoid the possibility of hematoma formation in this area.",
"     </li>",
"     <li>",
"      Routine nerve conduction studies are safe in patients with pacemakers, although high intensity proximal stimulation of nerves (for example, at Erb's point in the shoulder or stimulation at the root level) is avoided.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       EMG/NCS",
"      </span>",
"      can only evaluate large, myelinated neurons. Only a few nerves in the arms (median, radial, and ulnar) and legs (posterior tibial, deep peroneal, and sural) are routinely studied. These nerves are easily accessible to stimulation and are frequently involved in neurogenic illness. However, many diseases, especially those which are painful, affect smaller myelinated or unmyelinated nerve fibers, and",
"      <span class=\"nowrap\">",
"       EMG/NCS",
"      </span>",
"      may therefore be entirely normal. Thus, the absence of electrophysiologic evidence for a polyneuropathy does NOT mean that one does not exist.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       EMG/NCS",
"      </span>",
"      is an uncomfortable test; occasionally patients are unable to complete a study. The electromyographer must make choices between one test and another to avoid excessive procedures. In addition, evaluation of motor units may be difficult if patients are not able to provide good effort (activation) on the EMG portion of the study. Explaining the procedure ahead of time may avoid some of these difficulties.",
"     </li>",
"     <li>",
"      Electromyographers may have very limited training or may perform studies infrequently, which can lead to variable results. One study found that repeat",
"      <span class=\"nowrap\">",
"       EMG/NCS",
"      </span>",
"      resulted in a new diagnosis in 40 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8712/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of standard blood tests are available to help sort out peripheral nerve diseases. Studies can be obtained to evaluate for polyneuropathy, myopathy, and neuromuscular junction disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is also available for a number of illnesses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Charcot-Marie-Tooth type 1 is a hereditary demyelinating polyneuropathy. The electrophysiologic features are often suggestive, but genetic testing is commercially available. A duplication of the peripheral myelin protein 22 gene (PMP22) on chromosome 17 is the most common cause, although mutations on other chromosomes also exist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"       \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary polyneuropathy with predisposition to pressure palsies is a hereditary disease that is localized to the same gene as Charcot-Marie-Tooth Disease type 1a. Rather than a duplication of the gene, a deletion is present. These patients often have multiple entrapment neuropathies, including carpal tunnel syndrome, ulnar neuropathy at the elbow, and peroneal neuropathies at the fibular neck, superimposed upon a mild polyneuropathy. Abnormalities can be identified on EMG in asymptomatic individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21895?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of hereditary neuropathies\", section on 'Hereditary neuropathy with liability to pressure palsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 5 to 10 percent of amyotrophic lateral sclerosis (ALS) cases are familial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"       \"Familial amyotrophic lateral sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another syndrome, Kennedy's disease, is an X-linked form of motor neuron disease that is often associated with prominent bulbar signs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Genetic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myotonic dystrophy type 1 (DM1), the most common myotonic disorder, is caused by an excessively long repeat of a CTG sequence in a gene on chromosome 19 that likely codes for a protein kinase called myotonin. The length of the repeated CTG sequence correlates with the severity of disease. Genetic testing is also available for the less common myotonic dystrophy type 2 (DM2), which is caused by a CTG repeat expansion on chromosome 3. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"       \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dystrophin testing of blood and muscle can be performed to identify the X-linked disorders Duchenne and Becker muscular dystrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"       \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy may assist in the accurate diagnosis of myopathy. In patients with primary neurogenic disease, muscle biopsy may show fiber-type grouping or grouped atrophy. Muscle biopsy is also useful in patients evaluated for vasculitic polyneuropathy; inflammatory changes may be present in blood vessel walls of the muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nerve biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve biopsy is occasionally useful for diagnosing the underlying etiology of polyneuropathy for patients in whom it is difficult to define whether the process is predominantly axonal or demyelinating. Identifying demyelination with associated inflammation in these individuals may help guide treatment. As examples, the detection of inflammatory cells within the myelin sheath will lead to the diagnosis of demyelinating polyneuropathy when the",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    findings were not clear cut. Alternatively, amyloid may be identified, or there may be loss of a population of nerve fibers in some \"small-fiber\" neuropathies in which mainly unmyelinated axons are affected. However, in many situations, nonspecific or only minimal abnormalities may be found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of polyneuropathy\", section on 'Nerve biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermal skin biopsy is an especially useful test in the diagnosis of polyneuropathy that predominantly affects small, unmyelinated nerve fibers. Typical symptoms of small fiber neuropathy are distal burning, pain, numbness, and paresthesia. In patients with idiopathic painful distal sensory polyneuropathies who have a normal sural nerve biopsy, skin biopsy has demonstrated degeneration and loss of terminal nerve twigs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of polyneuropathy\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452077357\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diseases of the nerve (eg, polyneuropathy), muscle (eg, myopathy), and neuromuscular junction (eg, myasthenia gravis) may present with varying degrees of sensory loss and weakness. The neurologic examination should focus upon the distribution of muscle weakness, sensory loss, and pathologic deep tendon reflexes. Symptoms and signs of cranial nerve dysfunction can be useful in localizing the site of the problem. Proximal weakness often, but not always, points to a myopathy or neuromuscular junction disorder. Focal sensory loss in the absence of a known central nervous system lesion suggests a peripheral problem. In axonal polyneuropathies, a \"glove and stocking\" pattern of sensory loss, initially affecting the feet and later the hands, is a common finding. Nerve root lesions may cause sensory loss in a dermatomal pattern. Numbness in a single nerve territory suggests an entrapment neuropathy. Multiple areas of numbness in different extremities point to mononeuropathy multiplex. The loss of reflexes suggests a neuropathic lesion, generally affecting either sensory or motor fibers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical distinction between nerve, muscle and neuromuscular junction disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distinguishing peripheral from central nervous system (CNS) disease (eg, that due to stroke, brain tumor, or spinal cord lesions) is usually straightforward. Weakness or sensory loss confined to one limb generally suggests a peripheral nerve problem. The likelihood of a peripheral process is increased if there is associated pain in the extremity. However, localization is less clear when weakness or sensory loss involves more than one limb, or when",
"      <span class=\"nowrap\">",
"       pain/discomfort",
"      </span>",
"      is absent. In addition, a number of CNS disorders can be accompanied by varying types of pain. Examination of the deep tendon reflexes is the single most important test in determining whether a problem is peripheral or central. Brisk reflexes suggest central pathology. Hyporeflexia or areflexia points to a peripheral problem. Weakness caused by upper motor neuron (ie, CNS) problems generally follows a specific pattern in which weakness is predominant in extensor muscles in the arm (deltoid, triceps, wrist, and finger extensors) and flexor muscles in the leg (iliopsoas, hamstrings, and foot dorsiflexors). Increased tone on passive movement of the extremities also suggests a CNS process. Atrophy of muscles isolated to a specific root(s) or peripheral nerve places the problem in the peripheral nervous system. &nbsp;(See",
"      <a class=\"local\" href=\"#H11\">",
"       'Distinguishing peripheral from central nervous system disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of diagnostic tests are available to augment the history and physical examination in distinguishing between neurologic disorders. Electromyography and nerve conduction studies are among the most informative diagnostic tests for nerve and muscle disease. Genetic testing is also available for a number of illnesses. Muscle biopsy may assist in the accurate diagnosis of myopathy. For patients with polyneuropathy, nerve biopsy is occasionally helpful to define whether the process is predominantly axonal or demyelinating. Epidermal skin biopsy is an especially useful test in the diagnosis of polyneuropathy that predominantly affects small, unmyelinated nerve fibers. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8712/abstract/1\">",
"      Jabre JF, Dillard JW, Salzsieder BT, et al. The use of multiple Tinel's sign in the identification of patients with peripheral neuropathy. Electromyogr Clin Neurophysiol 1995; 35:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8712/abstract/2\">",
"      Tasker RR, DeCarvalho GT, Dolan EJ. Intractable pain of spinal cord origin: clinical features and implications for surgery. J Neurosurg 1992; 77:373.",
"     </a>",
"    </li>",
"    <li>",
"     Patten J. Neurological Differential Diagnosis, 2nd, Springer, New York 1996.",
"    </li>",
"    <li>",
"     Haerer AF. DeJong's The Neurologic Examination, 5th, Harper-Collins, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8712/abstract/5\">",
"      Rekand T, Gramstad A, Vedeler CA. Fatigue, pain and muscle weakness are frequent after Guillain-Barr&eacute; syndrome and poliomyelitis. J Neurol 2009; 256:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8712/abstract/6\">",
"      Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies in Guillain-Barr&eacute; syndrome: description and prognostic value. Ann Neurol 1988; 23:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5277 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8712=[""].join("\n");
var outline_f8_32_8712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H452077357\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL DISTINCTION BETWEEN NERVE, MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Motor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sensory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Reflexes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Additional signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Skin examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Points of confusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISTINGUISHING PERIPHERAL FROM CENTRAL NERVOUS SYSTEM DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Time course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other central nervous system disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Reflexes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Motor examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sensory examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Coordination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gait",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cranial nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other important distinctions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nerve biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452077357\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5277|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/20/32064\" title=\"picture 1\">",
"      Tinel test carpal tunnel",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=related_link\">",
"      Familial amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9417?source=related_link\">",
"      Gait disorders of elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21895?source=related_link\">",
"      Overview of hereditary neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8713="Role of radiation therapy in the management of melanoma";
var content_f8_32_8713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of radiation therapy in the management of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8713/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8713/contributors\">",
"     David E Wazer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8713/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8713/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8713/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/32/8713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, melanoma has been considered a relatively radioresistant tumor. Newer data have challenged this viewpoint, and radiation therapy (RT) is now considered to be a useful component of the therapeutic armamentarium for malignant melanoma. Most importantly, it can provide effective palliation for the 40 to 50 percent of patients who develop unresectable locally recurrent or metastatic disease producing bone pain, epidural spinal cord compression, central nervous system dysfunction due to brain involvement,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tumor hemorrhage.",
"   </p>",
"   <p>",
"    RT has also been applied after complete excision of a primary melanoma or after therapeutic lymphadenectomy for regional nodal disease as adjuvant therapy to reduce the rate of local recurrence for certain types of melanoma. Rarely, it has been used as a primary treatment for carefully selected melanomas.",
"   </p>",
"   <p>",
"    Here we will provide an overview of radiobiologic issues pertinent to the treatment of melanoma with RT and summarize the available data regarding efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADIOBIOLOGY OF MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited early clinical experience suggested that melanoma was radioresistant. This view was reinforced by radiobiologic data derived from irradiated melanoma cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These findings were thought to reflect an unusual repair capacity in melanoma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent in vitro studies on melanoma cell lines demonstrated widely differing radiation sensitivities that refuted the concept of melanoma as a uniformly radioresistant tumor. Instead, the available data raised the possibility that some melanoma cells exhibit a type of radioresponsiveness that is similar to that of \"late-reacting\" or slow-renewal normal tissues, requiring greater than standard doses per radiation fraction for most effective cell killing.",
"   </p>",
"   <p>",
"    A full discussion of radiobiology is beyond the scope of this review. Briefly, cellular survival following exposure to RT is described by a mathematic model termed a linear quadratic formula, in which cell survival is a function of radiation dose and two coefficients, alpha and beta [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/4\">",
"     4",
"    </a>",
"    ]. In these models, the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    ratio (in Gy) differs according to cell type, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slow renewal (late-responding) tissues of mesenchymal or ectodermal origin are characterized by a low",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      ratio (&lt;5 Gy); these tissues exhibit a greater repair capacity at lower radiation doses per fraction than fast renewal (early-responding) epithelial cell systems, which have a typical",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      value &gt;10 Gy.",
"     </li>",
"     <li>",
"      While early-responding tissues exhibit the greatest sensitivity to conventional radiation doses, late-responding tissues require larger than conventional fraction sizes.",
"     </li>",
"     <li>",
"      Most tumors have an",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      value that is greater than 10 Gy, while a significant fraction of melanoma cells have",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      values below 5 Gy, similar to late-responding normal tissues. These data imply that melanomas require higher than conventional fraction sizes to achieve effective cytotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms underlying the apparent relative radioresistance seen in melanomas remain poorly defined. In vitro, direct measures of melanoma cellular repair capacity (through quantitation of radiation induction and repair of DNA double strand breaks) and measures of cell recovery due to potentially lethal as well as sublethal damage repair suggest that repair of radiation-induced damage is performed with greater proficiency in melanoma than in other cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Human studies correlating dose per fraction with outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other tumor systems, in vitro radiobiologic parameters from melanoma cell lines are of limited value for predicting clinical responses to RT. As a result, attempts have been made to derive predictive radiobiologic data (ie, a correlation between dose per fraction and outcome) from clinical experience using multifraction RT courses to treat patients with melanoma. Such analyses have the potential to provide meaningful response data, provided sufficiently large sample sizes and consistent study endpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, tumor control probability (TCP) was estimated from 239 recurrent or metastatic lesions (127 cutaneous and 112 deeply seated) in 121 patients treated with RT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/7\">",
"     7",
"    </a>",
"    ]. The widely differing fractionation schedules used, and the finding that treatment time did not affect TCP, permitted an estimation of the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    ratio. This derived value was 0.57 Gy, which closely approximates the values found in cell culture systems. Using similar models, others have derived",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    ratios of 2.5 Gy for patients treated with RT for metastatic melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that in vivo as well as in cell culture systems melanomas exhibit the fractionation sensitivity of late-responding normal tissues, and support the hypothesis that melanomas should be more sensitive to larger rather than conventional fractions (eg, 6 Gy per fraction).",
"   </p>",
"   <p>",
"    Unfortunately, data derived from irradiated patients with melanoma provide conflicting data as to the benefit of larger than conventional fraction sizes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some data in patients with recurrent or metastatic melanoma support a higher likelihood of clinical benefit with larger than conventional fraction sizes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]. In the largest series of 618 RT-treated melanoma lesions, 48 percent achieved a complete response, which was durable at five years in 87 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/8\">",
"       8",
"      </a>",
"      ]. Among the parameters examined (total dose, treatment time, dose per fraction), only dose per fraction significantly correlated with clinical response; complete response rates were 59 and 33 percent for doses above and below 4 Gy, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These results have been called into question by the results of several single institutional clinical studies [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/11-14\">",
"       11-14",
"      </a>",
"      ] and a multicenter randomized phase III trial [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/15\">",
"       15",
"      </a>",
"      ], all of which fail to show better outcomes with larger fraction sizes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Radiation Therapy Oncology Group (RTOG) trial randomly assigned 137 patients with metastatic melanoma at any site other than abdomen or brain to four fractions of 8 Gy administered at weekly intervals or 20 fractions of 2.5 Gy each, administered daily five days per week [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no difference in the clinical response rate according to fraction size (24 and 23 percent, respectively); the duration of tumor control was not reported.",
"   </p>",
"   <p>",
"    At least some of this disparity may be due to the wide range of total doses used, some of which may have been inadequate to achieve tumor control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/9\">",
"     9",
"    </a>",
"    ]. Another factor is the time frame in which response has been assessed. In any tumor system, fraction sizes above 4 Gy, often delivered over a short time period, usually accelerate clinical tumor responses. However, because melanomas exhibit slow cell turnover similar to slow-renewal normal tissues, the delayed regression of melanoma lesions is likely to underestimate clinical benefit when the quality of the clinical response is judged at short time intervals (eg, three months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/10\">",
"     10",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    A third issue is that the importance of fraction size may be dependent upon the site of metastatic disease (ie,",
"    <span class=\"nowrap\">",
"     nodal/soft",
"    </span>",
"    tissue versus brain or bone metastases) (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Palliative RT'",
"    </a>",
"    below). Thus, the optimal method of delivering RT to patients with melanoma remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RESULTS OF RADIATION TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, melanoma is a radioresponsive tumor but the optimal total dose and fractionation remain uncertain. Retrospective clinical studies published before 1985 described success with RT schedules using larger than conventional fraction sizes, particularly greater than 4 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. However, these results are difficult to interpret:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients had advanced metastatic disease with a limited survival duration, and follow-up intervals were often short and insufficient to adequately assess tumor response. Follow-up duration is important because, as noted above, regression of radiated melanoma lesions can be slow, extending over months [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/11,17,19,20\">",
"       11,17,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The majority of early studies employed clinical response rates as endpoints for analysis rather than local tumor control. Reported tumor \"responses\" often included subjective pain relief rather than or in addition to objective measurement of the regression of lesions in skin or lymph nodes.",
"     </li>",
"     <li>",
"      RT has been administered in a wide variety of doses and fractionation regimens, often without regard for the site of metastatic disease. It may be necessary to individualize the fraction schedule to the nature of the melanoma lesion, because of substantial differences in radiosensitivities between cutaneous, lymph node or visceral metastases, and metastatic disease involving brain or bone [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/10,12,18,19\">",
"       10,12,18,19",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H14\">",
"       'Palliative RT'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Curative management of primary melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have suggested a role for RT as a primary treatment modality for certain melanomas (eg, superficial lentigo maligna and lentigo maligna melanoma) or as an adjuvant to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among cutaneous melanomas, superficial lentigo maligna (confined to the epidermis) and lentigo maligna melanoma (invasive into the dermis), which have a slow growth rate and low metastatic potential, have been treated successfully with RT. In one series of 51 patients with these lesions, a control rate of 92 percent was achieved in the 46 evaluable patients using orthovoltage radiation with doses between 35 Gy in one week and 50 Gy in three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/22\">",
"     22",
"    </a>",
"    ]. The choice of fractionation schedules was dependent upon field size. There were four local recurrences that were salvaged with further treatment, and only one patient developed regional and distant metastases.",
"   </p>",
"   <p>",
"    These favorable results were confirmed in a second series of 64 patients with either lentigo maligna (n = 42) or lentigo maligna melanoma (n = 22), who received 100 Gy of orthovoltage RT in ten fractions (10 Gy per fraction, five days per week for two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/23\">",
"     23",
"    </a>",
"    ]. All patients with lentigo maligna melanoma underwent excision of the nodular component of their disease prior to beginning RT. There were only two local recurrences among those with lentigo maligna melanoma, both of which were salvaged surgically; one patient developed metastatic disease without a local recurrence.",
"   </p>",
"   <p>",
"    There are limited data regarding the effectiveness of RT for the more deeply invasive nodular melanomas. In one series of 95 cases, high radiation doses (100 to 110 Gy) were delivered in 6 Gy fractions using superficial 60 kVp x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/19\">",
"     19",
"    </a>",
"    ]. The five-year survival rate was 68 percent, a value similar to that obtained with wide local excision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .) This observation suggests that RT may be as effective as tumor excision in some cases, although confirmatory randomized trials are not available.",
"   </p>",
"   <p>",
"    Mucosal melanomas are relatively rare, representing only 4 percent of all melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/24\">",
"     24",
"    </a>",
"    ]. Surgery is the first choice of therapy for mucosal melanomas of the head and neck. However, if resection cannot be accomplished, RT may be used to achieve local control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/25\">",
"     25",
"    </a>",
"    ]. Carbon ion therapy may offer some advantages, but remains experimental. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link&amp;anchor=H20#H20\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Mucosal melanomas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link&amp;anchor=H17#H17\">",
"     \"Proton and ion beams in cancer therapy\", section on 'Mucosal melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among series that evaluate the role of RT alone with curative intent for mucosal melanoma, the largest included 28 patients with nasal cavity and paranasal sinus tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/26\">",
"     26",
"    </a>",
"    ]. The actuarial local control rate using a treatment schedule of 50 to 55 Gy in 15 to 16 fractions was 49 percent at three years. Similar results were noted in another report of 25 patients in whom local control was achieved in 44 percent after a severely hypofractionated schedule of 8 Gy delivered on days 0, 7, and 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adjuvant RT of the primary site",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is often recommended after complete resection of primary melanomas that are associated with a high rate of local recurrence despite apparently adequate surgical excision. This includes melanomas with desmoplastic or neurotropic features, thick lesions (&gt;4 mm) particularly if ulcerated or associated with satellitosis, and melanomas arising from the head and neck particularly those involving mucosal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Desmoplastic melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although randomized trials have not been conducted, a benefit for RT in improving local control in these settings has been suggested in uncontrolled series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/30,31,33-36\">",
"     30,31,33-36",
"    </a>",
"    ]. As an example, mucosal head and neck melanomas are associated with a high rate of local disease recurrence, even if the primary lesion is small and the regional nodes uninvolved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/31,37\">",
"     31,37",
"    </a>",
"    ]. Adjuvant RT decreases the likelihood of local recurrence after complete resection, but does not impact on survival, in part because of the high rate of systemic relapse in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/21,31,35,36\">",
"     21,31,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a retrospective series of 69 patients with primary mucosal melanoma of the head and neck treated at the Institute Gustave Roussy over a 18-year period, 30 of whom had surgery alone and 39 postoperative radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/31\">",
"     31",
"    </a>",
"    ]. Despite significantly more locally advanced",
"    <span class=\"nowrap\">",
"     (T3/T4)",
"    </span>",
"    tumors in the radiotherapy group, the five-year local control rates were significantly better than with surgery alone (62 versus 23 percent). However, survival was worse in the RT group (median 17 versus 30 months), likely attributed to the higher number of locally advanced lesions and the greater risk of distant relapse in this group. Other reports note a link between improved local control and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT may also be considered in patients with microscopic or macroscopically positive margins if further surgical clearance is not feasible. However, reresection is preferred, if at all possible.",
"   </p>",
"   <p>",
"    RT is used infrequently for the treatment of in transit metastases, and its use is limited to situations in which disease is too extensive for surgical excision and isolated limb perfusion is either not possible or unavailable. In such cases, RT may provide palliative benefit and occasionally, prolonged regional control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link\">",
"     \"Cutaneous melanoma: Management of in transit metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant RT may be considered in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following resection of melanomas with desmoplastic or neurotropic features",
"     </li>",
"     <li>",
"      Thick melanomas (&gt;4 mm) particularly if ulcerated or associated with satellitosis",
"     </li>",
"     <li>",
"      Melanomas arising from the head and neck particularly those involving mucosal sites",
"     </li>",
"     <li>",
"      Inability to achieve negative resection margins",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Regionally metastatic melanoma: irradiation of high-risk nodal basins",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is rarely indicated as definitive management of melanoma metastatic to regional lymph nodes (stage III disease, (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"UTD.htm?7/61/8157\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74203 \" href=\"UTD.htm?34/20/35149\">",
"     table 2",
"    </a>",
"    )). Surgical excision provides superior local control (in at least 85 percent of cases) as well as important diagnostic and prognostic information.",
"   </p>",
"   <p>",
"    Several features increase the rate of locoregional recurrence to 30 to 50 percent following regional lymphadenectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extracapsular lymph node extension (ECE) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      &ge;4 involved nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/38,39,41\">",
"       38,39,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bulky adenopathy (&ge;3 cm in size) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/39,40,42,43\">",
"       39,40,42,43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cervical lymph node location [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/39,42,44-46\">",
"       39,42,44-46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recurrent nodal disease",
"     </li>",
"     <li>",
"      Positive sentinel lymph node and complete node dissection not planned",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of one or more of these factors is also associated with an increased risk for non-nodal, locoregional recurrence in the skin and dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/47\">",
"     47",
"    </a>",
"    ], and ECE is an independent variable for systemic relapse as well [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Locoregional relapses may be difficult to manage because they are often refractory to therapy and produce substantial morbidity such as bleeding, infection of ulcerated tumor, limb edema, pain, plexopathy, or paralysis. As a result, prevention of locoregional failure would probably improve quality of life if it could be achieved with a well tolerated regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies suggested that adjuvant regional RT following surgery decreased the rate of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/44,48-50\">",
"     44,48-50",
"    </a>",
"    ], but this finding has not been seen in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjuvant RT was studied in a phase III trial conducted primarily in Australia and New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/52\">",
"     52",
"    </a>",
"    ]. Following surgical resection, 250 patients with clinically positive lymph nodes (head and neck, axilla, or groin) deemed to be at high risk for locoregional recurrence were randomly assigned to RT (48 Gy in 20 fractions) or observation. Patients were considered at high risk if there was extranodal spread of melanoma, multiple nodes involved, or large nodes with disease; those with only a positive sentinel lymph node biopsy were excluded.",
"   </p>",
"   <p>",
"    Overall, 109 patients assigned to RT and 108 assigned to observation were evaluable. At a median follow-up of 40 months, the risk of relapse in the regional lymph nodes was significantly reduced with adjuvant radiation therapy compared to observation (20 relapses versus 34 relapses, hazard ratio [HR] 0.56, 95% CI 0.32-0.98). However, there were not significant differences in relapse-free survival or overall survival (70 versus 73 events, HR 0.91, and 59 versus 47 deaths, HR 1.37).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adjuvant RT plus interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon its demonstrated survival benefit in Eastern Cooperative Oncology Group (ECOG) trial 1684, systemic administration of high-dose interferon alfa (IFNa) is typically recommended for patients who undergo resection of node-positive melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, ECOG 1684, the only trial to show a survival benefit for adjuvant IFNa in this setting, excluded patients with ECE. As a result, there are no data evaluating the role of IFNa in preventing systemic or locoregional recurrence in patients with advanced regional nodal disease, such as ECE, and standard therapy has not yet been defined for such patients.",
"   </p>",
"   <p>",
"    The Eastern Cooperative Oncology Group (ECOG) and RTOG jointly initiated a randomized comparison of high-dose IFNa plus radiation therapy (30 Gy in five fractions) versus IFNa alone for patients estimated to have a locoregional recurrence risk of 30 to 50 percent (one or more nodes containing metastatic melanoma with evidence of gross extracapsular extension, nodal recurrence after previous lymphadenectomy). Unfortunately, the trial was closed due to lack of accrual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cutaneous melanoma of the head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies have yielded conflicting results about the role of RT in improving locoregional disease control in patients with melanoma of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/44,48,49,51\">",
"     44,48,49,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series from M D Anderson Cancer Center, 267 patients with melanoma metastases limited to the cervical lymph nodes underwent surgical resection followed by a course of hypofractionated RT (6 Gy per fraction twice a week, to a total dose of 24 to 30 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/53\">",
"       53",
"      </a>",
"      ]. At a median follow-up of 50 months, the five year actuarial locoregional control and disease-specific survival rates were 91 and 49 percent, respectively. These results compared favorably with historical controls from the same institution.",
"     </li>",
"     <li>",
"      In contrast, a study from the Sydney Melanoma Unit compared 587 patients treated with surgery alone to 129 patients who were treated with postoperative hypofractionated RT (typically 5.5 Gy twice a week for three weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/51\">",
"       51",
"      </a>",
"      ]. No benefit was seen either in terms of locoregional control or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized phase III trial conducted primarily in Australia and New Zealand addressing the role of adjuvant radiation therapy has completed enrollment but results are not yet available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/51\">",
"     51",
"    </a>",
"    ]. Another trial conducted by the Radiation Therapy Oncology Group was terminated prematurely because of slow accrual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adjuvant interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon its demonstrated survival benefit in Eastern Cooperative Oncology Group (ECOG) trial 1684, systemic administration of high-dose interferon alfa (IFNa) is typically recommended for patients who undergo resection of node-positive melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, ECOG 1684, the only trial to show a survival benefit for adjuvant IFNa in this setting, excluded patients with ECE. As a result, there are no data evaluating the role of IFNa in preventing systemic or locoregional recurrence in patients with advanced regional nodal disease, such as ECE, and standard therapy has not yet been defined for such patients.",
"   </p>",
"   <p>",
"    The Eastern Cooperative Oncology Group (ECOG) and RTOG commenced and subsequently closed a randomized comparison of high-dose IFNa plus radiation therapy (30 Gy in five fractions) versus IFNa alone for patients estimated to have a locoregional recurrence risk of 30 to 50 percent (one or more nodes containing metastatic melanoma with evidence of gross extracapsular extension, nodal recurrence after previous lymphadenectomy). Unfortunately, the trial was closed due to lack of accrual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Palliative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the available data suggest that the radioresponsiveness of metastatic melanoma is dependent upon the site of disease involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cutaneous and lymph node metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic spread to skin and lymph nodes occurs in approximately 50 percent of patients with cutaneous melanoma, and is associated with a better median survival than with visceral or skeletal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/54\">",
"     54",
"    </a>",
"    ]. Overall complete and partial response rates to RT in such patients range from 59 to 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/10,48,54\">",
"     10,48,54",
"    </a>",
"    ]. A large dose per fraction (&gt;4 Gy) may be more effective for cutaneous melanoma lesions and superficial skin metastases, a finding consistent with the radiobiologic data described above. However, each case must be individualized with respect to the choice of fraction size and total dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Visceral, cerebral, and skeletal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral metastases (stage IV disease) often respond to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/10,55\">",
"     10,55",
"    </a>",
"    ]. At least one report suggests that large doses per fraction may be beneficial for patients with visceral metastases to the lung, liver, abdominal and pelvic structures, and mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/55\">",
"     55",
"    </a>",
"    ]. The likelihood of response was much higher in patients who received fractional doses above 4 Gy compared to lower doses (82 versus 44 percent). The choice of large fractions in patients with visceral metastases must be individualized to the clinical situation and the structures to be irradiated. The use of large dose per fraction in treating these anatomic sites may be particularly appropriate in the setting of tumor-related hemorrhage.",
"   </p>",
"   <p>",
"    By contrast, the degree of palliative benefit for brain and bone metastases appears to be relatively independent of fraction size, and there is no evidence that one fractionation schedule is superior to another [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/12,55-57\">",
"     12,55-57",
"    </a>",
"    ]. As a result, radiation regimens commonly used for nonmelanoma metastases, 30 Gy in 10 to 12 fractions, are reasonable since they minimize the potential for late tissue complications associated with dose fractions above 4 Gy. Symptomatic response rates among patients with multiple brain metastases treated with RT range from 39 to 76 percent.",
"   </p>",
"   <p>",
"    RT may also be beneficial following resection of a solitary brain metastasis. This topic, as well as stereotactic radiosurgery for brain metastases, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of brain metastases in melanoma\", section on 'Adjuvant WBRT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful palliation of painful skeletal metastases can be obtained using RT in 50 to 86 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/12,55-57\">",
"     12,55-57",
"    </a>",
"    ]. No particular fractionation technique has proven more effective (eg, &gt;4 versus &le;4 Gy) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/12,55,57\">",
"     12,55,57",
"    </a>",
"    ]. In at least one report, symptom palliation was more successful for extremity compared to axial lesions (88 versus 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     IRRADIATION AND HYPERTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia in the temperature range from 40 to 45&ordm;C is cytotoxic, producing more than two-log cell kill of human melanoma cells after a one hour exposure at 45&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/58\">",
"     58",
"    </a>",
"    ]. However, as with the sensitivity to irradiation, there is major variation among human melanoma cell lines in their sensitivity to heat [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interest in combining heat and irradiation stemmed in part from the perceived radioresistance of melanoma, but was primarily motivated by the observation of the complementarity of heat-induced and RT-induced injury. The mechanisms underlying resistance to damage by irradiation and heat are different; thus, radioresistant cells may remain sensitive to heat as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell cycle phases that are relatively resistant to RT are sensitive to heat [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low tissue pH desensitizes tissues to the cytotoxic effects of RT but increases their sensitivity to heat [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although cellular repair functions do not necessarily correlate with radiosensitivity, one mechanism of hyperthermic radiosensitization is inhibition of repair of potentially lethal and sublethal damage [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. The impairment of repair, which may be mediated in part by inhibition of DNA polymerases, is similar in radiosensitive and radioresistant cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of hyperthermia and irradiation is at least additive, and heat is one of the best radiosensitizers available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/65\">",
"     65",
"    </a>",
"    ]. In a clinical study comparing the dose-response curves for 134 melanoma lesions treated with RT alone or combined with hyperthermia, there was a clinically derived therapeutic enhancement ratio of approximately 2.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this compelling rationale and encouraging preclinical data, the results of clinical studies combining heat and RT in the treatment of melanoma have been complex and somewhat contradictory [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/54,66-70\">",
"     54,66-70",
"    </a>",
"    ]. At least one randomized trial of RT with or without hyperthermia was conducted by the European Society for Hyperthermic Oncology in 70 patients with metastatic or recurrent melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/66\">",
"     66",
"    </a>",
"    ]. The addition of hyperthermia to RT (three fractions of 8 to 9 Gy) increased the complete response rate from 35 to 62 percent, and two-year local control rates from 28 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/66\">",
"     66",
"    </a>",
"    ]. However, only 14 percent of patients received the prescribed protocol treatment because of \"equipment difficulties\", and survival did not differ between the two groups. The importance of heating technique has been demonstrated in many different clinical scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While hyperthermia is routinely used in conjunction with RT for palliative treatment of melanoma in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8713/abstract/65,68\">",
"     65,68",
"    </a>",
"    ], it is not widely used in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early clinical experience suggested that melanoma was a radioresistant tumor. However, subsequent preclinical and clinical studies indicate that melanoma may be sensitive to radiation therapy (RT), particularly when greater than standard doses of radiation are administered in each fraction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Radiobiology of melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RT only rarely has a role in the primary management of melanomas, although it occasionally is used in patients with mucosal melanomas that are not amenable to surgical resection. RT may also have a role as adjuvant therapy after surgery for primary melanomas that are associated with a high rate of local recurrence despite apparently adequate excision. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Curative management of primary melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjuvant RT can decrease the incidence of regional lymph node recurrence in patients with positive regional nodes in their initial surgical specimen. However, there is no evidence of any improvement in relapse-free or overall survival. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Adjuvant RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RT can provide useful palliation for patients with bone, brain, and visceral metastases. Whether larger dose fractions improve palliation in these settings is unclear. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Visceral, cerebral, and skeletal metastases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link\">",
"       \"Management of brain metastases in melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/1\">",
"      Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 1971; 31:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/2\">",
"      Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol 1971; 44:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/3\">",
"      Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol 1986; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/4\">",
"      Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/5\">",
"      Little JB, Hahn GM, Frindel E, Tubiana M. Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 1973; 106:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/6\">",
"      ELKIND MM, SUTTON-GILBERT H, MOSES WB, et al. RADIATION RESPONSE OF MAMMALIAN CELLS GROWN IN CULTURE. V. TEMPERATURE DEPENDENCE OF THE REPAIR OF X-RAY DAMAGE IN SURVIVING CELLS (AEROBIC AND HYPOXIC). Radiat Res 1965; 25:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/7\">",
"      Bentzen SM, Overgaard J, Thames HD, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 1989; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/8\">",
"      Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986; 12:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/9\">",
"      Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/10\">",
"      Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/11\">",
"      Trott KR, von Lieven H, Kummermehr J, et al. The radiosensitivity of malignant melanomas part II: clinical studies. Int J Radiat Oncol Biol Phys 1981; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/12\">",
"      Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 1988; 61:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/13\">",
"      Nambisan RN, Alexiou G, Reese PA, Karakousis CP. Early metastatic patterns and survival in malignant melanoma. J Surg Oncol 1987; 34:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/14\">",
"      Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/15\">",
"      Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/16\">",
"      Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980; 6:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/17\">",
"      Habermalz HJ, Fischer JJ. Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer 1976; 38:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/18\">",
"      Hornsey S. The relationship between total dose, number of fractions and fractions size in the response of malignant melanoma in patients. Br J Radiol 1978; 51:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/19\">",
"      HELLRIEGEL W. Radiation therapy of primary and metastatic melanoma. Ann N Y Acad Sci 1963; 100:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/20\">",
"      Pyrh&ouml;nen SO, Kajanti MJ. The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 1992; 24:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/21\">",
"      Trotti A, Peters LJ. Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol 1993; 9:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/22\">",
"      Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983; 9:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/23\">",
"      Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/24\">",
"      Iversen K, Robins RE. Mucosal malignant melanomas. Am J Surg 1980; 139:660.",
"     </a>",
"    </li>",
"    <li>",
"     Balch C, Houghton A, Sober A. Radiotherapy for melanoma. In: Cutaneous Melanoma, JB Lippincott, Philadelphia 1992. p.509.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/26\">",
"      Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 1991; 64:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/27\">",
"      Harwood AR, Cummings BJ. Radiotherapy for mucosal melanomas. Int J Radiat Oncol Biol Phys 1982; 8:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/28\">",
"      Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park) 2004; 18:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/29\">",
"      Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985; 11:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/30\">",
"      Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003; 25:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/31\">",
"      Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005; 103:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/32\">",
"      Newlin HE, Morris CG, Amdur RJ, Mendenhall WM. Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol 2005; 28:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/33\">",
"      DICKSON RJ. Malignant melanoma; a combined surgical and radiotherapeutic approach. Am J Roentgenol Radium Ther Nucl Med 1958; 79:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/34\">",
"      Johanson CR, Harwood AR, Cummings BJ, Quirt I. 0-7-21 radiotherapy in nodular melanoma. Cancer 1983; 51:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/35\">",
"      Kingdom TT, Kaplan MJ. Mucosal melanoma of the nasal cavity and paranasal sinuses. Head Neck 1995; 17:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/36\">",
"      Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/37\">",
"      Lee SP, Shimizu KT, Tran LM, et al. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope 1994; 104:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/38\">",
"      Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/39\">",
"      Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/40\">",
"      Shen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 2000; 7:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/41\">",
"      Miller EJ, Daly JM, Synnestvedt M, et al. Loco-regional nodal relapse in melanoma. Surg Oncol 1992; 1:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/42\">",
"      Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma. J Surg Oncol 1993; 54:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/43\">",
"      Beadle BM, Guadagnolo BA, Ballo MT, et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009; 73:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/44\">",
"      Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003; 97:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/45\">",
"      Bowsher WG, Taylor BA, Hughes LE. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986; 73:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/46\">",
"      O'Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991; 162:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/47\">",
"      Cascinelli N, Bufalino R, Marolda R, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/48\">",
"      Corry J, Smith JG, Bishop M, Ainslie J. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999; 44:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/49\">",
"      Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/50\">",
"      Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 2006; 81:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/51\">",
"      Moncrieff MD, Martin R, O'Brien CJ, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol 2008; 15:3022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/52\">",
"      Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/53\">",
"      Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006; 64:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/54\">",
"      Schmidt-Ullrich RK, Johnson CR. Role of radiotherapy and hyperthermia in the management of malignant melanoma. Semin Surg Oncol 1996; 12:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/55\">",
"      Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys 1981; 7:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/56\">",
"      Dougherty MJ, Kligerman MM. Radiotherapy of melanoma. Cancer Treat Res 1993; 65:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/57\">",
"      Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988; 15:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/58\">",
"      Roizin-Towle L, Pirro JP. The response of human and rodent cells to hyperthermia. Int J Radiat Oncol Biol Phys 1991; 20:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/59\">",
"      Bichay TJ, Feeley MM, Raaphorst GP. A comparison of heat sensitivity, radiosensitivity and PLDR in four human melanoma cell lines. Melanoma Res 1992; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/60\">",
"      Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE. Cellular responses to combinations of hyperthermia and radiation. Radiology 1977; 123:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/61\">",
"      Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1971; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/62\">",
"      Gerweck L, Rottinger E. Enhancement of mammalian cell sensitivity to hyperthermia by pH alteration. Radiat Res 1976; 67:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/63\">",
"      Raaphorst GP, Mao JP, Ng CE. Repair of potentially lethal damage: its inhibition by hyperthermia in two human melanoma cell lines with different radio- and heat sensitivities. Melanoma Res 1993; 3:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/64\">",
"      Raaphorst GP, Mao JP, Ng CE. Sublethal radiation damage repair and its inhibition by hyperthermia in two human melanoma cell lines of different radiosensitivities. Melanoma Res 1994; 4:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/65\">",
"      van der Zee J. Heating the patient: a promising approach? Ann Oncol 2002; 13:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/66\">",
"      Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/67\">",
"      Perez CA, Pajak T, Emami B, et al. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol 1991; 14:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/68\">",
"      Kroon BB, Bergman W, Coebergh JW, Ruiter DJ. Consensus on the management of malignant melanoma of the skin in The Netherlands. Dutch Melanoma Working Party. Melanoma Res 1999; 9:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/69\">",
"      Engin K, Tupchong L, Waterman FM, et al. Hyperthermia and radiation in advanced malignant melanoma. Int J Radiat Oncol Biol Phys 1993; 25:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8713/abstract/70\">",
"      Shidnia H, Hornback NB, Shen RN, et al. An overview of the role of radiation therapy and hyperthermia in treatment of malignant melanoma. Adv Exp Med Biol 1990; 267:531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7614 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8713=[""].join("\n");
var outline_f8_32_8713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADIOBIOLOGY OF MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Human studies correlating dose per fraction with outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RESULTS OF RADIATION TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Curative management of primary melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - RT alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adjuvant RT of the primary site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Regionally metastatic melanoma: irradiation of high-risk nodal basins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adjuvant RT plus interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cutaneous melanoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adjuvant interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Palliative RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cutaneous and lymph node metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Visceral, cerebral, and skeletal metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      IRRADIATION AND HYPERTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 2\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8714="Clinical presentation and diagnosis of primary gastrointestinal lymphomas";
var content_f8_32_8714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8714/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8714/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8714/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/32/8714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/32/8714/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/32/8714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal (GI) tract is the predominant site of extranodal lymphoma involvement. Primary lymphomas of the GI tract are rare, while secondary GI involvement is relatively common. Despite their rarity, primary lymphomas of the GI tract are important since their evaluation, diagnosis, management and prognosis are distinct from that of lymphoma at other sites and other cancers of the GI tract.",
"   </p>",
"   <p>",
"    The definition of primary GI lymphoma has differed among authors, but typically refers to a lymphoma that predominantly involves any section of the GI tract from the oropharynx to the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While the disease typically involves a single primary site, multiple sites within the GI tract may be involved, as can local and distant lymph nodes. The vast majority are non-Hodgkin lymphomas (NHLs), although Hodgkin lymphoma has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GI lymphomas typically present with nonspecific signs and symptoms attributable to the site of involvement. This topic review will discuss the salient clinical features and diagnostic evaluation of GI lymphomas. The management of GI lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal (GI) tract is the predominant site of extranodal non-Hodgkin lymphomas (NHLs) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/5\">",
"     5",
"    </a>",
"    ]. Primary NHLs of the GI tract are rare, accounting for only 1 to 4 percent of malignancies arising in the stomach, small intestine, or colon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, secondary GI involvement is relatively common, occurring in approximately 10 percent of patients with limited stage NHL at the time of diagnosis, and up to 60 percent of those dying from advanced NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two largest studies of GI lymphoma reported the following sites of involvement in Greek and German populations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stomach &mdash; 68 to 75 percent",
"     </li>",
"     <li>",
"      Small bowel (including duodenum) &mdash; 9 percent",
"     </li>",
"     <li>",
"      Ileo-cecal region &mdash; 7 percent",
"     </li>",
"     <li>",
"      More than one GI site &mdash; 6 to 13 percent",
"     </li>",
"     <li>",
"      Rectum &mdash; 2 percent",
"     </li>",
"     <li>",
"      Diffuse colonic involvement &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the distribution of primary GI lymphomas varies among populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States (US), gastric lymphoma is the most common extranodal site of lymphoma. The vast majority of these lesions are either extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) type or diffuse large B cell lymphoma.",
"     </li>",
"     <li>",
"      Primary small intestinal lymphoma, while uncommon in Western countries, accounts for up to 75 percent of primary GI lymphomas in the Middle East and Mediterranean basin.",
"     </li>",
"     <li>",
"      The incidence of Burkitt lymphoma (BL) in Africa is approximately 50-fold higher than it is in the US. The classic GI presentation is that of an obstructing lesion in the terminal ileum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predisposing conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions that predispose to GI lymphoma have been identified. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Helicobacter pylori infection",
"      </strong>",
"      &mdash; H pylori infection is highly associated with the development of MALT lymphoma of the stomach and, to a lesser degree, other sites in the GI tract. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link&amp;anchor=H12#H12\">",
"       \"Association between Helicobacter pylori infection and gastrointestinal malignancy\", section on 'Gastric lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Autoimmune diseases",
"      </strong>",
"      &mdash; A variety of autoimmune diseases, including rheumatoid arthritis, Sj&ouml;gren's syndrome, systemic lupus erythematosus and granulomatosis with polyangiitis (previously Wegener's granulomatosis), have been associated with an increased risk of lymphoma. Immunosuppressive therapy, rather than the disease itself, is thought to be responsible for the increased risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Past history'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Immunodeficiency and immunosuppression",
"      </strong>",
"      &mdash; Congenital immunodeficiency syndromes (eg, Wiskott-Aldrich syndrome, severe combined immunodeficiency syndrome, ataxia-telangiectasia, X-linked agammaglobulinemia) and acquired immunodeficiency (eg, HIV infection, iatrogenic immunosuppression) are associated with an increased incidence of B cell lymphoma. Lymphomas occurring in this setting tend to be aggressive and widespread at the time of diagnosis. Although most such patients have secondary GI tract involvement, primary involvement of the stomach and small bowel has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/10-16\">",
"       10-16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"       \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"       \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Celiac disease",
"      </strong>",
"      &mdash; Patients with gluten-sensitive enteropathy (celiac sprue) are at increased risk of developing enteropathy-associated T cell lymphoma (EATL) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/17\">",
"       17",
"      </a>",
"      ]. Population-based studies suggest that celiac disease is also associated with an increased risk of B cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/18\">",
"       18",
"      </a>",
"      ]. The extent to which coincident autoimmune or inflammatory disorders contribute to this risk is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      EATL is an uncommon sequela of enteropathy, occurring in approximately 5 percent of patients with celiac sprue followed for a 30-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Ulcerative enteritis, another complication of long-standing celiac sprue, is probably a variant of EATL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of celiac disease in adults\", section on 'Ulcerative jejunitis and intestinal lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Inflammatory bowel disease",
"      </strong>",
"      &mdash; An association between inflammatory bowel disease (IBD) and lymphoma has been described in several reports, most of which were retrospective, small, and derived from tertiary referral centers, raising the possibility of referral bias. In contrast, large population-based studies have found relative risks ranging from 0.4 to 2.4 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/4,21-27\">",
"       4,21-27",
"      </a>",
"      ]. Considering the data in aggregate, they do not support an increased risk of lymphoma in patients with IBD compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Whether the risk of lymphoma is increased in patients with IBD treated with classic immunosuppressive agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 6-mercaptopurine) or tumor necrosis factor-alpha inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ) remains an unresolved concern [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Although most studies published on immunosuppressive agents to date have found no increased risk, they lack sufficient power to provide conclusive data. A meta-analysis of six cohort studies suggested a fourfold increased risk of lymphoma in IBD patients treated azathioprine or 6-MP [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/31\">",
"       31",
"      </a>",
"      ]. A possible association between tumor necrosis factor-alpha inhibitors and lymphoma is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link&amp;anchor=H10#H10\">",
"       \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\", section on 'Lymphoma risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nodular lymphoid hyperplasia",
"      </strong>",
"      &mdash; Nodular lymphoid hyperplasia, also known as follicular lymphoid hyperplasia, is a benign condition that has been implicated as a possible risk factor for primary lymphomas of the small intestine (",
"      <a class=\"graphic graphic_picture graphicRef80570 \" href=\"UTD.htm?33/4/33870\">",
"       picture 1",
"      </a>",
"      ). In children, nodular lymphoid hyperplasia tends to have a benign course and usually regresses spontaneously; in adults, however, the condition is often associated with immunodeficiency (eg, common variable immunodeficiency or selective IgA deficiency) and giardiasis, and the prognosis is less certain. Curiously, although the association between nodular lymphoid hyperplasia with humoral immunodeficiency and primary intestinal lymphoma remains controversial, the evidence is stronger for an association of nodular lymphoid hyperplasia with GI lymphoma in the absence of immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/32-37\">",
"       32-37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary esophageal lymphoma is very rare, accounting for less than 1 percent of primary GI lymphomas. More commonly, lymphoma may involve the esophagus as an extension of mediastinal or gastric involvement. Only case reports and series of primary esophageal lymphoma have been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/38\">",
"     38",
"    </a>",
"    ]. Primary esophageal lymphoma appears to more commonly involve the distal esophagus. Most patients are asymptomatic or present with complaints of dysphagia or odynophagia. There is a diverse appearance on imaging and the diagnosis is made by endoscopic biopsy in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GASTRIC LYMPHOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach is the most common extranodal site of lymphoma and accounts for 68 to 75 percent of GI lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Primary gastric lymphoma accounts for 3 percent of gastric neoplasms and 10 percent of lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/40\">",
"     40",
"    </a>",
"    ]. Gastric lymphoma reaches its peak incidence between the ages of 50 to 60 years. There is a slight male predominance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gastric lymphoma typically present with nonspecific symptoms frequently seen with more common gastric conditions, such as peptic ulcer disease, gastric adenocarcinoma, and nonulcer dyspepsia. The most common presenting symptoms include (",
"    <a class=\"graphic graphic_table graphicRef68593 \" href=\"UTD.htm?30/61/31708\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/8,41-44\">",
"     8,41-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epigastric pain or discomfort (78 to 93 percent)",
"     </li>",
"     <li>",
"      Anorexia (47 percent)",
"     </li>",
"     <li>",
"      Weight loss (25 percent)",
"     </li>",
"     <li>",
"      Nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting (18 percent)",
"     </li>",
"     <li>",
"      Occult gastrointestinal bleeding (19 percent)",
"     </li>",
"     <li>",
"      Early satiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic B symptoms (fever, night sweats) are seen in 12 percent of patients. Weight loss is frequently due to local compromise of GI structures and is not always considered a B symptom in this setting. Hematemesis and melena are uncommon. The duration of symptoms preceding the diagnosis is quite variable, ranging from a few days to six years.",
"   </p>",
"   <p>",
"    The physical examination is often normal, but may reveal a palpable mass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral lymphadenopathy when the disease is advanced. Laboratory studies also tend to be normal at presentation. Anemia or an elevated erythrocyte sedimentation rate may be present in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gastric lymphoma is usually established during upper endoscopy with biopsy. While it can be suggested by findings on imaging, biopsy is required for a definitive diagnosis. Laparotomy and laparoscopy are typically reserved for patients with complications such as perforation or obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on upper endoscopy are diverse and may include any of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucosal erythema (",
"      <a class=\"graphic graphic_picture graphicRef81847 \" href=\"UTD.htm?30/41/31376\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A mass or polypoid lesion with or without ulceration",
"     </li>",
"     <li>",
"      Benign-appearing gastric ulcer (",
"      <a class=\"graphic graphic_picture graphicRef70267 \" href=\"UTD.htm?9/12/9422\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nodularity",
"     </li>",
"     <li>",
"      Thickened, cerebroid gastric folds (",
"      <a class=\"graphic graphic_picture graphicRef53702 graphicRef65490 \" href=\"UTD.htm?10/9/10390\">",
"       picture 4A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple biopsies should be obtained from the stomach, duodenum, gastroesophageal junction and from abnormal appearing lesions. An endoscopic ultrasound should determine the depth of invasion and the presence of perigastric nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/47-51\">",
"     47-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern seen on endoscopic ultrasound (EUS) may correlate with the type of lymphoma that is present. In one series, for example, superficial spreading or diffuse infiltrating lesions on EUS were seen with MALT lymphoma, while mass-forming lesions were typical of diffuse large B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic evaluation is required for the determination of lymph node involvement. EUS alone has suboptimal accuracy in distinguishing benign from malignant lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. When combined with endoscopic biopsy, however, overall accuracy approaches 90 percent (versus 66 percent for EUS alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/52\">",
"     52",
"    </a>",
"    ]. Even higher accuracy rates may be achievable if flow cytometry is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, caution is warranted in the interpretation of findings using EUS or CT alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Upper GI series",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on upper GI series include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mass or filling defect &mdash; over 70 percent of cases",
"     </li>",
"     <li>",
"      Ulcerated lesion &mdash; 40 percent",
"     </li>",
"     <li>",
"      Diffuse infiltration &mdash; 20 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73837 graphicRef78916 \" href=\"UTD.htm?21/27/21941\">",
"       image 1A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any of these findings should heighten suspicion of gastric lymphoma, but none is diagnostic. The extension of a lesion across the pylorus into the duodenum is highly suggestive, but again not pathognomonic of lymphoma. Patients with any of the described findings should undergo endoscopy with biopsy to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gastric lymphoma may be suggested by endoscopic and imaging findings, but must be confirmed by biopsy. Both suspicious appearing lesions and normal appearing mucosa should be biopsied since gastric lymphoma can occasionally present as multifocal disease with involvement of tissue that appears to be unaffected on initial visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopists should aim to attain the largest biopsy specimen possible. Conventional pinch biopsies may miss the diagnosis, since gastric lymphoma can infiltrate the submucosa without affecting the mucosa; this problem is most likely to occur when no obvious mass is present. Jumbo biopsies, snare biopsies, biopsies within biopsies (\"well technique\"), and needle aspiration can all serve to increase the yield in such cases. Endoscopic ultrasound (EUS)-guided fine needle aspiration biopsy (FNAB) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/60-62\">",
"     60-62",
"    </a>",
"    ] or endoscopic submucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/63\">",
"     63",
"    </a>",
"    ] may provide even greater diagnostic capability.",
"   </p>",
"   <p>",
"    The vast majority (greater than 90 percent) of gastric lymphomas are approximately equally divided into two histologic subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extranodal marginal zone B cell lymphoma of mucosa (gut)-associated lymphoid tissue (MALT) type (previously called MALToma, MALT-type lymphoma, or MALT lymphoma) (38 to 48 percent) (",
"      <a class=\"graphic graphic_table graphicRef78881 \" href=\"UTD.htm?38/25/39323\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse large B cell lymphoma (45 to 59 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remaining cases of gastric lymphoma may represent any histology, but the most commonly seen are [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mantle cell lymphoma (1 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Follicular lymphoma (0.5 to 2 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral T cell lymphoma (1.5 to 4 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LYMPHOMA OF THE SMALL INTESTINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of GI lymphomas occur in the small intestine. These lymphomas may be broadly categorized into three main groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoproliferative small intestinal disease (IPSID, also called alpha heavy chain disease, Mediterranean lymphoma, Seligmann disease) lymphoma is a variant of extranodal marginal zone lymphoma of MALT which secretes alpha heavy chains. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=see_link&amp;anchor=H9#H9\">",
"       \"The heavy chain diseases\", section on 'Alpha HCD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteropathy-associated T cell lymphoma (EATL), also called intestinal T cell lymphoma, is a tumor that is highly associated with gluten-sensitive enteropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other western-type non-IPSID lymphomas (eg, diffuse large B cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, follicular lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/64\">",
"       64",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic features of small intestine lymphomas differ with the population studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Middle East and Mediterranean basin, primary small intestinal lymphoma, usually of the immunoproliferative small intestinal disease (IPSID) type, accounts for up to 75 percent of primary GI lymphomas. There is a male predominance with a median age at presentation of 25 years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/65\">",
"       65",
"      </a>",
"      ]. Low socioeconomic status, poor sanitation, and high rates of endemic parasitic infestation and infantile infectious enteritis are common among high-risk populations. Genetic factors (eg, linkage with HLA-Aw19, -B12, -A9 haplotypes), as well as Campylobacter infection, have also been implicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Campylobacter jejuni'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although uncommon, enteropathy-associated T cell lymphoma (EATL) is most common in areas with a high incidence of gluten-sensitive enteropathy (celiac sprue), such as the Western part of Ireland and Northern Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/66\">",
"       66",
"      </a>",
"      ]. EATL is most commonly found in adult males with a median age at diagnosis in the sixth decade [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/19,20,66\">",
"       19,20,66",
"      </a>",
"      ]. Ulcerative enteritis, another complication of long-standing celiac sprue, is probably a variant of EATL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In industrialized nations, small intestinal lymphomas are rare, not of the IPSID type, and typically occur in middle-aged men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with lymphoma of the small intestine differs according to the histologic tumor type. The duration of symptoms prior to diagnosis ranges from a few days to a few years. The different features of immunoproliferative small intestinal disease (IPSID) and non-IPSID associated lymphoma are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76348 \" href=\"UTD.htm?24/10/24747\">",
"     table 3",
"    </a>",
"    ). Abdominal pain is a frequent symptom of all types, occurring in approximately two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with IPSID typically present with abdominal pain, chronic diarrhea, malabsorption, severe weight loss, clubbing, and ankle edema. Unusual manifestations include lactose intolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/67\">",
"       67",
"      </a>",
"      ], enteroenteric fistulae [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/68\">",
"       68",
"      </a>",
"      ], ascites, fever, hypocalcemia, steatorrhea, and organomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with enteropathy-associated T cell lymphoma (EATL) often present with acute bleeding, obstruction, or perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Clinical deterioration of celiac disease, despite compliance with a gluten-free diet, should raise suspicion of the possible presence of lymphoma. Conversely, since celiac disease may be undiagnosed at the time of presentation of the intestinal lymphoma, it has been suggested that patients with a T cell lymphoma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a gut primary localization should be tested for the presence of underlying celiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with other non-IPSID lymphomas have a more nonspecific presentation, which may include abdominal pain, GI bleeding, intestinal obstruction or perforation, obstructive jaundice,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a palpable abdominal mass [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/64,65,70\">",
"       64,65,70",
"      </a>",
"      ]. In contrast, patients with primary intestinal follicular lymphoma are often diagnosed during endoscopy performed for symptoms unrelated to the lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a suspected lymphoma of the small intestine may include a contrast-enhanced computed tomography (CT), positron emission tomography (PET), contrast radiography, conventional endoscopy, and capsule endoscopy. CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contrast radiography are usually the initial diagnostic modalities performed. Diagnostic laparotomy with resection of the involved bowel is appropriate if there is obstruction, perforation, or major bleeding at presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on CT are varied and may include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/39,72\">",
"     39,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple, large tumors",
"     </li>",
"     <li>",
"      Bowel segments with lumen that is narrowed, enlarged, or both",
"     </li>",
"     <li>",
"      Mesenteric nodal masses resulting in the \"hamburger\" or \"sandwich\" sign in which nodal masses (the bun) surround the mesenteric vessels (the meat of the hamburger)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of particular concern are bowel wall segments with homogenous thickening, greater than 2 cm, with a normal or enlarged lumen. The presence of any of the above findings necessitates further evaluation and biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14415676\">",
"    <span class=\"h3\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on positron emission tomography (PET) in patients with lymphoma of the small intestine vary depending upon the pathologic subtype. In general, PET scanning detects clinically aggressive non-Hodgkin lymphoma variants as well as most Hodgkin lymphoma subtypes, while its overall usefulness in the clinically indolent lymphomas remains unclear. The use of PET in the staging of lymphoma is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'PET scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the histologies most commonly seen in the small intestine, diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), and enteropathy associated T cell lymphoma (EATL) are typically FDG-avid [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/73\">",
"     73",
"    </a>",
"    ]. In contrast, marginal zone lymphoma (MZL) and follicular lymphoma (FL) have variable FDG-avidity. &nbsp;",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the use of PET in the evaluation of patients with small bowel lymphoma in particular. Importantly, interpretation of FDG-avidity in the gastrointestinal tract may be complicated by the presence of FDG activity reflecting normal metabolic activity in the bowel or increased FDG activity related to inflammatory conditions (eg, Crohn&rsquo;s disease), infections, or other bowel pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/74\">",
"     74",
"    </a>",
"    ]. The following studies have addressed the use of PET in patients with GI lymphoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 33 patients with GI tract lymphoma, six of which were in the small bowel, focal nodular or diffuse hypermetabolic activity was universally seen in the GI tract of patients with biopsy-proven DLBCL (16 patients), MCL (6 patients), and peripheral T cell lymphoma (3 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/75\">",
"       75",
"      </a>",
"      ]. In contrast, FDG activity was variable in patients with MZL (5 patients), FL (2 patients), and small lymphocytic lymphoma (1 patient).",
"     </li>",
"     <li>",
"      In a prospective study, patients with biopsy-proven extranodal MZL underwent PET scans as part of their initial staging studies [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/76\">",
"       76",
"      </a>",
"      ]. The study was closed early when none of the first 10 consecutive patients demonstrated FDG activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We typically incorporate PET imaging into the pretreatment evaluation of patients with DLBCL of the GI tract. The use of PET in the pretreatment evaluation of patients with other GI lymphoma subtypes is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Contrast radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns demonstrated on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies of patients with lymphoma of the small intestine include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/39,72\">",
"     39,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple nodules or polyps",
"     </li>",
"     <li>",
"      Bowel wall and fold thickening",
"     </li>",
"     <li>",
"      Ulcerations and strictures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IPSID-associated lymphomas generally appear as a diffuse infiltrating lesion of the proximal small intestine, sometimes resembling cobblestoning. The presence of multiple polyps of varying size within the bowel (lymphomatous polyposis) is particularly common in mantle cell lymphoma. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Endoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although technically difficult, endoscopic evaluation of the small bowel with biopsy of lesions can be diagnostic. Endoscopic approaches depending upon the site of involvement. Proximal small bowel lesions may be detected by \"push\" enteroscopy, while lesions in the distal small bowel may be assessed with intubation of the terminal ileum during colonoscopy.",
"   </p>",
"   <p>",
"    Capsule endoscopy is another useful technique for evaluating the small bowel in patients with suggestive clinical presentations or suspicious radiographic findings. Unlike other endoscopic approaches, however, capsule endoscopy does not permit tissue sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different histologic variants of lymphoma present with typical findings on endoscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with enteropathy-associated T cell lymphoma of the jejunum typically demonstrate large circumferential ulcers without overt tumor masses. Biopsies of the involved mucosa demonstrate lymphoma, while biopsies of the normal appearing mucosa usually show villous atrophy characteristic of celiac disease.",
"     </li>",
"     <li>",
"      Patients with mantle cell lymphoma may demonstrate typical small nodular or polypoid tumors (2 mm to more than 2 cm in size), with or without normal intervening mucosa referred to as \"lymphomatous polyposis\" (",
"      <a class=\"graphic graphic_picture graphicRef64338 \" href=\"UTD.htm?6/41/6814\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with primary intestinal follicular lymphoma most commonly present with multiple small (1 to 5 mm) polypoid lesions in the descending part of the duodenum, with some cases demonstrating clustering around the ampulla of Vater [",
"      <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/71\">",
"       71",
"      </a>",
"      ]. The lesions are solitary in approximately 15 percent of cases and may grossly resemble an adenoma. Other segments of the small bowel (eg, jejunum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ileum) are involved in approximately 17 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Barium studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    studies may suggest the diagnosis of small intestinal lymphoma but cannot reliably differentiate lymphoma from other conditions. In mantle cell lymphoma, barium radiographs of the small bowel may show numerous round filling defects in the lumen or a tumor mass in the terminal ileum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exploratory laparotomy should be performed when the lesion is not accessible via endoscopy or when endoscopic biopsies are unavailable or non-diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Obstructing lesions also require laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are typically normal in patients with small bowel lymphoma with the exception of alpha heavy chain paraproteinemia in immunoproliferative small intestinal disease (IPSID)-associated disease. Alpha heavy chain paraproteinemia (alpha heavy chain disease) is present in up to 70 percent of IPSID-associated lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/65\">",
"     65",
"    </a>",
"    ]. The paraproteinemia may diminish or disappear as IPSID progresses from an early prelymphomatous stage to frank lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=see_link&amp;anchor=H9#H9\">",
"     \"The heavy chain diseases\", section on 'Alpha HCD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of small intestinal lymphoma is dependent upon the pathological review of an adequate biopsy specimen. The main histologic subtypes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoproliferative small intestinal disease lymphoma, which is a variant of extranodal marginal zone lymphoma of MALT (IPSID, also called alpha heavy chain disease, Mediterranean lymphoma, Seligmann disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=see_link&amp;anchor=H9#H9\">",
"       \"The heavy chain diseases\", section on 'Alpha HCD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteropathy-associated T cell lymphoma (EATL), also called intestinal T cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other western-type non-IPSID lymphomas:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diffuse large B cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mantle cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Burkitt lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Follicular lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H99000111#H99000111\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Primary intestinal follicular lymphoma'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COLORECTAL LYMPHOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal lymphoma is uncommon, accounting for approximately 3 percent of the GI lymphomas and 0.3 percent of large intestinal malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. There is a male predominance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with colorectal lymphoma can present with abdominal pain, overt or occult bleeding, diarrhea, intussusception (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64048 graphicRef75825 \" href=\"UTD.htm?1/35/1586\">",
"     image 2A-B",
"    </a>",
"    ), or rarely, bowel obstruction (",
"    <a class=\"graphic graphic_table graphicRef68593 \" href=\"UTD.htm?30/61/31708\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/2,8,42,54,79-82\">",
"     2,8,42,54,79-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endemic Burkitt lymphoma is a disease of childhood with a peak incidence at about eight years of age. GI manifestations are infrequent but may include obstruction or intussusception. In contrast, sporadic Burkitt lymphoma exhibits a wider age distribution, with only 50 percent of cases affecting children. It often presents with abdominal pain (",
"    <a class=\"graphic graphic_picture graphicRef69159 \" href=\"UTD.htm?32/60/33728\">",
"     picture 6",
"    </a>",
"    ) and obstructive symptoms caused by ileocecal involvement. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy with biopsy is the principal diagnostic modality for colorectal lymphomas. Colonoscopic findings may include diffuse mucosal nodularity, colitis-like changes with induration and ulceration, or a mass with or without ulceration (",
"    <a class=\"graphic graphic_picture graphicRef67755 graphicRef72196 \" href=\"UTD.htm?41/25/42384\">",
"     picture 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/83\">",
"     83",
"    </a>",
"    ]. Multiple biopsies of all lesions should be performed using standard techniques. Computed tomography (CT) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema may suggest the diagnosis with areas of focal mucosal nodularity, polypoid masses, mucosal fold thickening, extracolonic masses, or circumferential infiltrates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55178 \" href=\"UTD.htm?2/10/2223\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/32/8714/abstract/39,84\">",
"     39,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical small nodular or polypoid tumors (2 mm to more than 2 cm in size), with or without normal intervening mucosa, can be seen by colonoscopy (",
"    <a class=\"graphic graphic_picture graphicRef64338 \" href=\"UTD.htm?6/41/6814\">",
"     picture 5",
"    </a>",
"    ) or enteroscopy in mantle cell lymphoma. Locoregional mesenteric lymphadenopathy is often present at the time of diagnosis, and involvement of liver, spleen, bone marrow, and peripheral nodes may be evident early in the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of colorectal lymphoma is dependent upon the histologic evaluation of an adequate biopsy specimen. The most common histologies seen in this region include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mantle cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Burkitt lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Follicular lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diffuse large B cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphomas of the gastrointestinal (GI) tract are lymphomas that predominantly involve any section of the GI tract. While the disease involves a single primary site, multiple sites within the GI tract may be involved, as can local and distant lymph nodes.",
"   </p>",
"   <p>",
"    The GI tract is the most common site of primary extranodal lymphoma and the vast majority are non-Hodgkin lymphomas. The most common site of involvement is the stomach (70 percent) followed by the small bowel, colon, rectum, and esophagus. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Distribution'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presenting symptoms, appropriate investigation, and pathology vary by site of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric lymphoma is the most common site of GI lymphoma and typically presents with nonspecific symptoms such as epigastric pain or discomfort, anorexia, weight loss, nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting, occult GI bleeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      early satiety. The diagnosis is usually established during upper endoscopy with biopsy. The vast majority (greater than 90 percent) of gastric lymphomas are approximately equally divided between extranodal marginal zone B cell lymphoma of mucosa (gut)-associated lymphoid tissue (MALT) type and diffuse large B cell lymphoma. The remaining cases may represent any histology. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastric lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphoma of the small intestine is the second most common site and the clinical presentation varies depending upon whether the tumor is associated with immunoproliferative small intestinal disease (IPSID), celiac disease (enteropathy-associated T cell lymphoma, EATL), or neither (",
"      <a class=\"graphic graphic_table graphicRef76348 \" href=\"UTD.htm?24/10/24747\">",
"       table 3",
"      </a>",
"      ). The diagnosis may be suggested on computed tomography (CT)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      contrast radiography, but requires a biopsy for confirmation. The most common histologic types include IPSID-related lymphoma, EATL, diffuse large B cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, and follicular lymphoma. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Lymphoma of the small intestine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colorectal lymphoma is an uncommon form of GI lymphoma and may present with abdominal pain, overt or occult bleeding, diarrhea, intussusception, or rarely, bowel obstruction. Colonoscopy with biopsy is the principal diagnostic modality for colorectal lymphomas. The most common histologies include diffuse large B cell lymphoma, mantle cell lymphoma, and Burkitt lymphoma. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Colorectal lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal lymphoma is perhaps the most uncommon site for primary GI lymphoma and appears to more commonly involve the distal esophagus. Most patients are asymptomatic or present with complaints of dysphagia or odynophagia. There is a diverse appearance on imaging and the diagnosis is made by endoscopic biopsy in most cases. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Esophageal lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/1\">",
"      DAWSON IM, CORNES JS, MORSON BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961; 49:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/2\">",
"      Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978; 42:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/3\">",
"      Devaney K, Jaffe ES. The surgical pathology of gastrointestinal Hodgkin's disease. Am J Clin Pathol 1991; 95:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/4\">",
"      Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/5\">",
"      Paryani S, Hoppe RT, Burke JS, et al. Extralymphatic involvement in diffuse non-Hodgkin's lymphoma. J Clin Oncol 1983; 1:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/6\">",
"      Loehr WJ, Mujahed Z, Zahn FD, et al. Primary lymphoma of the gastrointestinal tract: a review of 100 cases. Ann Surg 1969; 170:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/7\">",
"      Ehrlich AN, Stalder G, Geller W, Sherlock P. Gastrointestinal manifestations of malignant lymphoma. Gastroenterology 1968; 54:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/8\">",
"      Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/9\">",
"      Papaxoinis G, Papageorgiou S, Rontogianni D, et al. Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 2006; 47:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/10\">",
"      Aull MJ, Buell JF, Peddi VR, et al. MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation 2003; 75:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/11\">",
"      Kaslikova J, Kocandrle V, Zastava V, et al. Multiple immunoblastic sarcoma of the small intestine following renal transplantation. Transplantation 1981; 31:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/12\">",
"      McTamaney JP, Neifeld JP, Mendez-Picon G, Lee HM. Primary gastric lymphoma following renal transplantation. J Surg Oncol 1981; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/13\">",
"      Jamieson NV, Thiru S, Calne RY, Evans DB. Gastric lymphomas arising in two patients with renal allografts. Transplantation 1981; 31:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/14\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/15\">",
"      Sandler AS, Kaplan LD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Hematol Oncol Clin North Am 1996; 10:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/16\">",
"      Andrews CN, John Gill M, Urbanski SJ, et al. Changing epidemiology and risk factors for gastrointestinal non-Hodgkin's lymphoma in a North American population: population-based study. Am J Gastroenterol 2008; 103:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/17\">",
"      Smedby KE, Akerman M, Hildebrand H, et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005; 54:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/18\">",
"      Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002; 287:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/19\">",
"      Swinson CM, Slavin G, Coles EC, Booth CC. Coeliac disease and malignancy. Lancet 1983; 1:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/20\">",
"      Cooper BT, Holmes GK, Ferguson R, Cooke WT. Celiac disease and malignancy. Medicine (Baltimore) 1980; 59:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/21\">",
"      Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/22\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/23\">",
"      Persson PG, Karl&eacute;n P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/24\">",
"      Karl&eacute;n P, L&ouml;fberg R, Brostr&ouml;m O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999; 94:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/25\">",
"      Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000; 95:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/26\">",
"      Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/27\">",
"      Chiorean MV, Pokhrel B, Adabala J, et al. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci 2011; 56:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/28\">",
"      Loftus EV Jr, Sandborn WJ. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology 2001; 121:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/29\">",
"      Disanti W, Rajapakse RO, Korelitz BI, et al. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/30\">",
"      Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/31\">",
"      Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/32\">",
"      Rambaud JC, De Saint-Louvent P, Marti R, et al. Diffuse follicular lymphoid hyperplasia of the small intestine without primary immunoglobulin deficiency. Am J Med 1982; 73:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/33\">",
"      Hermans PE, Diaz-Buxo JA, Stobo JD. Idiopathic late-onset immunoglobulin deficiency. Clinical observations in 50 patients. Am J Med 1976; 61:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/34\">",
"      Ajdukiewicz AB, Youngs GR, Bouchier IA. Nodular lymphoid hyperplasia with hypogammaglobulinaemia. Gut 1972; 13:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/35\">",
"      Matuchansky C, Touchard G, Lemaire M, et al. Malignant lymphoma of the small bowel associated with diffuse nodular lymphoid hyperplasia. N Engl J Med 1985; 313:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/36\">",
"      Harris M, Blewitt RW, Davies VJ, Steward WP. High-grade non-Hodgkin's lymphoma complicating polypoid nodular lymphoid hyperplasia and multiple lymphomatous polyposis of the intestine. Histopathology 1989; 15:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/37\">",
"      Castellano G, Moreno D, Galvao O, et al. Malignant lymphoma of jejunum with common variable hypogammaglobulinemia and diffuse nodular hyperplasia of the small intestine. A case study and literature review. J Clin Gastroenterol 1992; 15:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/38\">",
"      Kalogeropoulos IV, Chalazonitis AN, Tsolaki S, et al. A case of primary isolated non-Hodgkin's lymphoma of the esophagus in an immunocompetent patient. World J Gastroenterol 2009; 15:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/39\">",
"      Ghai S, Pattison J, Ghai S, et al. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. Radiographics 2007; 27:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/40\">",
"      Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/41\">",
"      Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991; 101:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/42\">",
"      Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/43\">",
"      Muller AF, Maloney A, Jenkins D, et al. Primary gastric lymphoma in clinical practice 1973-1992. Gut 1995; 36:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/44\">",
"      Wang T, Gui W, Shen Q. Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis. Med Oncol 2010; 27:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/45\">",
"      Spinelli P, Lo Gullo C, Pizzetti P. Endoscopic diagnosis of gastric lymphomas. Endoscopy 1980; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/46\">",
"      Fork FT, Haglund U, H&ouml;gstr&ouml;m H, Wehlin L. Primary gastric lymphoma versus gastric cancer. An endoscopic and radiographic study of differential diagnostic possibilities. Endoscopy 1985; 17:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/47\">",
"      Tio TL, den Hartog Jager FC, Tijtgat GN. Endoscopic ultrasonography of non-Hodgkin lymphoma of the stomach. Gastroenterology 1986; 91:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/48\">",
"      Caletti G, Ferrari A, Brocchi E, Barbara L. Accuracy of endoscopic ultrasonography in the diagnosis and staging of gastric cancer and lymphoma. Surgery 1993; 113:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/49\">",
"      Fujishima H, Misawa T, Maruoka A, et al. Staging and follow-up of primary gastric lymphoma by endoscopic ultrasonography. Am J Gastroenterol 1991; 86:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/50\">",
"      Suekane H, Iida M, Yao T, et al. Endoscopic ultrasonography in primary gastric lymphoma: correlation with endoscopic and histologic findings. Gastrointest Endosc 1993; 39:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/51\">",
"      Fischbach W, Goebeler-Kolve ME, Greiner A. Diagnostic accuracy of EUS in the local staging of primary gastric lymphoma: results of a prospective, multicenter study comparing EUS with histopathologic stage. Gastrointest Endosc 2002; 56:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/52\">",
"      Harada N, Wiersema M, Wiersema L. Endosonography guided fine needle aspiration biopsy (EUS FNA) in the evaluation of lymphadenopathy: Staging accuracy of EUS FNA versus EUS alone. Gastrointest Endosc 1997; 45:AB31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/53\">",
"      Wiersema MJ, Gatzimos K, Nisi R, Wiersema LM. Staging of non-Hodgkin's gastric lymphoma with endosonography-guided fine-needle aspiration biopsy and flow cytometry. Gastrointest Endosc 1996; 44:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/54\">",
"      Haber DA, Mayer RJ. Primary gastrointestinal lymphoma. Semin Oncol 1988; 15:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/55\">",
"      Menuck LS. Gastric lymphoma, a radiologic diagnosis. Gastrointest Radiol 1976; 1:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/56\">",
"      Marshak RH, Lindner AE, Maklansky D. Lymphosarcoma of the stomach. Am J Gastroenterol 1976; 66:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/57\">",
"      Sato T, Sakai Y, Ishiguro S, Furukawa H. Radiologic manifestations of early gastric lymphoma. AJR Am J Roentgenol 1986; 146:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/58\">",
"      Park MS, Kim KW, Yu JS, et al. Radiographic findings of primary B-cell lymphoma of the stomach: low-grade versus high-grade malignancy in relation to the mucosa-associated lymphoid tissue concept. AJR Am J Roentgenol 2002; 179:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/59\">",
"      Wotherspoon AC, Doglioni C, Isaacson PG. Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): a multifocal disease. Histopathology 1992; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/60\">",
"      Chang KJ, Katz KD, Durbin TE, et al. Endoscopic ultrasound-guided fine-needle aspiration. Gastrointest Endosc 1994; 40:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/61\">",
"      Wiersema MJ, Kochman ML, Cramer HM, et al. Endosonography-guided real-time fine-needle aspiration biopsy. Gastrointest Endosc 1994; 40:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/62\">",
"      Vilmann P, Hancke S, Henriksen FW, Jacobsen GK. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of lesions in the upper gastrointestinal tract. Gastrointest Endosc 1995; 41:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/63\">",
"      Suekane H, Iida M, Kuwano Y, et al. Diagnosis of primary early gastric lymphoma. Usefulness of endoscopic mucosal resection for histologic evaluation. Cancer 1993; 71:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/64\">",
"      Mori M, Kobayashi Y, Maeshima AM, et al. The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma. Ann Oncol 2010; 21:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/65\">",
"      Salem P, el-Hashimi L, Anaissie E, et al. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. Cancer 1987; 59:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/66\">",
"      Verbeek WH, Van De Water JM, Al-Toma A, et al. Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol 2008; 43:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/67\">",
"      Nasrallah SM. Lactose intolerance in the Lebanese population and in \"Mediterranean lymphoma\". Am J Clin Nutr 1979; 32:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/68\">",
"      Vessal K, Dutz W, Kohout E, Rezvani L. Immunoproliferative small intestinal disease with duodenojejunal lymphoma: radiologic changes. AJR Am J Roentgenol 1980; 135:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/69\">",
"      Nassar VH, Salem PA, Shahid MJ, et al. \"Mediterranean abdominal lymphoma\" or immunoproliferative small intestinal disease. Part II: pathological aspects. Cancer 1978; 41:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/70\">",
"      Ross WA, Egwim CI, Wallace MJ, et al. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci 2010; 55:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/71\">",
"      Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 2011; 29:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/72\">",
"      Mendelson RM, Fermoyle S. Primary gastrointestinal lymphomas: a radiological-pathological review. Part 2: Small intestine. Australas Radiol 2006; 50:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/73\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/74\">",
"      Cronin CG, Scott J, Kambadakone A, et al. Utility of positron emission tomography/CT in the evaluation of small bowel pathology. Br J Radiol 2012; 85:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/75\">",
"      Phongkitkarun S, Varavithya V, Kazama T, et al. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 2005; 11:7284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/76\">",
"      Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/77\">",
"      Flieger D, Keller R, May A, et al. Capsule endoscopy in gastrointestinal lymphomas. Endoscopy 2005; 37:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/78\">",
"      Khojasteh A, Haghshenass M, Haghighi P. Current concepts immunoproliferative small intestinal disease. A \"Third-World lesion\". N Engl J Med 1983; 308:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/79\">",
"      Glick DD, Soule EH. Primary malignant lymphoma of colon or appendix. Report of 27 cases. Arch Surg 1966; 92:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/80\">",
"      Perry PM, Cross RM, Morson BC. Primary malignant lymphoma of the rectum (22 cases). Proc R Soc Med 1972; 65:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/81\">",
"      Henry CA, Berry RE. Primary lymphoma of the large intestine. Am Surg 1988; 54:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/82\">",
"      Avil&eacute;s A, Neri N, Huerta-Guzm&aacute;n J. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients. J Surg Oncol 2002; 80:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/83\">",
"      Myung SJ, Joo KR, Yang SK, et al. Clinicopathologic features of ileocolonic malignant lymphoma: analysis according to colonoscopic classification. Gastrointest Endosc 2003; 57:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/32/8714/abstract/84\">",
"      Mendelson RM, Fermoyle S. Primary gastrointestinal lymphomas: a radiological-pathological review. Part 1: Stomach, oesophagus and colon. Australas Radiol 2005; 49:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4743 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-26410B5948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8714=[""].join("\n");
var outline_f8_32_8714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predisposing conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ESOPHAGEAL LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GASTRIC LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Upper GI series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LYMPHOMA OF THE SMALL INTESTINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14415676\">",
"      - Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Contrast radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Barium studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Laparotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COLORECTAL LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4743|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/13/15569\" title=\"diagnostic image 1A\">",
"      Gastric MALT lymphoma UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/44/37583\" title=\"diagnostic image 1B\">",
"      Gastric lymphoma UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/58/31662\" title=\"diagnostic image 2A\">",
"      Intussusception lymphoma BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/26/27055\" title=\"diagnostic image 2B\">",
"      Intussusception lymphoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/10/2223\" title=\"diagnostic image 3\">",
"      Colorectal lymphoma BE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4743|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/4/33870\" title=\"picture 1\">",
"      Lymphoid hyperplasia TI Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/41/31376\" title=\"picture 2\">",
"      Gastric MALT lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/12/9422\" title=\"picture 3\">",
"      Ulcerated MALT lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/42/676\" title=\"picture 4A\">",
"      Gastric large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/56/29582\" title=\"picture 4B\">",
"      Gastric large cell lymphoma II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/41/6814\" title=\"picture 5\">",
"      Mantle cell lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/60/33728\" title=\"picture 6\">",
"      Burkitt lymphoma endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/35/4670\" title=\"picture 7A\">",
"      Non Hodgkins lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/52/17231\" title=\"picture 7B\">",
"      NHL rectum Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/61/31708\" title=\"table 1\">",
"      Symptoms GI lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/25/39323\" title=\"table 2\">",
"      Grading GI MALT lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/10/24747\" title=\"table 3\">",
"      Features of IPSID lymphomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=related_link\">",
"      Epidemiology, clinical features, and types of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=related_link\">",
"      The heavy chain diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_32_8715="Staging system retroperit sarc";
var content_f8_32_8715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The Dutch/Memorial Sloan-Kettering cancer center classification system for retroperitoneal soft tissue sarcomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        Low-grade, complete resection, no metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        High-grade, complete resection, no metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        Any grade, incomplete resection, no metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        Any grade, any resection, distant metastases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: van Dalen T, Van Coevorden F, et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol 2004; 11:483.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8715=[""].join("\n");
var outline_f8_32_8715=null;
var title_f8_32_8716="Linear scanning echoendoscopes";
var content_f8_32_8716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Linear scanning echoendoscopes currently available in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        GF-UC140-AL5",
"       </td>",
"       <td class=\"subtitle1\">",
"        GF-UCT140P-AL5",
"       </td>",
"       <td class=\"subtitle1\">",
"        EG-3630UR",
"       </td>",
"       <td class=\"subtitle1\">",
"        EG-3830UT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        US scanning orientation and range",
"       </td>",
"       <td>",
"        Electronic linear 180 degrees",
"       </td>",
"       <td>",
"        Electronic linear 180 degrees",
"       </td>",
"       <td>",
"        Electronic linear 120 degrees",
"       </td>",
"       <td>",
"        Electronic linear 120 degrees",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopic image",
"       </td>",
"       <td>",
"        Video oblique forward",
"       </td>",
"       <td>",
"        Video oblique forward",
"       </td>",
"       <td>",
"        Video oblique forward",
"       </td>",
"       <td>",
"        Video oblique forward",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biopsy channel size",
"       </td>",
"       <td>",
"        2.8 mm",
"       </td>",
"       <td>",
"        3.7 mm",
"       </td>",
"       <td>",
"        2.4 mm",
"       </td>",
"       <td>",
"        3.8 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevator",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doppler/color Doppler",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        US scanning frequency (MHz)",
"       </td>",
"       <td>",
"        5, 6, 7.5, 10",
"       </td>",
"       <td>",
"        5, 6, 7.5, 10",
"       </td>",
"       <td>",
"        5, 7.5, 10",
"       </td>",
"       <td>",
"        5, 7.5, 10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Maurits J. Wiersema, MD., with data from: Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography, Gress, F, Bhattacharya, I (Eds), Blackwell Science, Malden, MA 2001. p.136.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8716=[""].join("\n");
var outline_f8_32_8716=null;
var title_f8_32_8717="Amphetamine structure";
var content_f8_32_8717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amphetamine structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 168px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8717=[""].join("\n");
var outline_f8_32_8717=null;
var title_f8_32_8718="Eval acute asthma attack";
var content_f8_32_8718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Formal evaluation of asthma exacerbation severity in the urgent or emergency care setting",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subset: respiratory arrest imminent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Breathlessness",
"       </td>",
"       <td>",
"        While walking",
"       </td>",
"       <td>",
"        While at rest (infant - softer, shorter cry, difficulty feeding)",
"       </td>",
"       <td>",
"        While at rest (infant - stops feeding)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can lie down",
"       </td>",
"       <td>",
"        Prefers sitting",
"       </td>",
"       <td>",
"        Sits upright",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Talks in",
"       </td>",
"       <td>",
"        Sentences",
"       </td>",
"       <td>",
"        Phrases",
"       </td>",
"       <td>",
"        Words",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alertness",
"       </td>",
"       <td>",
"        May be agitated",
"       </td>",
"       <td>",
"        Usually agitated",
"       </td>",
"       <td>",
"        Usually agitated",
"       </td>",
"       <td>",
"        Drowsy or confused",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        Respiratory rate",
"       </td>",
"       <td rowspan=\"7\">",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Often &gt;30/minute",
"       </td>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         Guide to rates of breathing in awake children:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Age",
"       </td>",
"       <td>",
"        Normal rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;2 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;60/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2-12 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;50/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1-5 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;40/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6-8 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;30/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use of accessory muscles; suprasternal retractions",
"       </td>",
"       <td>",
"        Usually not",
"       </td>",
"       <td>",
"        Commonly",
"       </td>",
"       <td>",
"        Usually",
"       </td>",
"       <td>",
"        Paradoxical thoracoabdominal movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wheeze",
"       </td>",
"       <td>",
"        Moderate, often only end expiratory",
"       </td>",
"       <td>",
"        Loud; throughout exhalation",
"       </td>",
"       <td>",
"        Usually loud; throughout inhalation and exhalation",
"       </td>",
"       <td>",
"        Absence of wheeze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"6\">",
"        Pulse/minute",
"       </td>",
"       <td rowspan=\"6\">",
"        &lt;100",
"       </td>",
"       <td>",
"        100-120",
"       </td>",
"       <td>",
"        &gt;120",
"       </td>",
"       <td rowspan=\"6\">",
"        Bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         Guide to normal pulse rates in children:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Age",
"       </td>",
"       <td>",
"        Normal rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2-12 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;160/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1-2 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;120/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2-8 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;110/minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulsus paradoxus",
"       </td>",
"       <td>",
"        Absent &lt;10 mmHg",
"       </td>",
"       <td>",
"        <p>",
"         May be present",
"        </p>",
"        <p>",
"         10-25 mmHg",
"        </p>",
"       </td>",
"       <td>",
"        Often present",
"        <p>",
"         &gt;25 mmHg (adult)",
"        </p>",
"        <p>",
"         20-40 mmHg (child)",
"        </p>",
"       </td>",
"       <td>",
"        Absence suggests respiratory muscle fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Functional assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PEF percent predicted or percent personal best",
"       </td>",
"       <td>",
"        &ge;70 percent",
"       </td>",
"       <td>",
"        Approx. 40-69 percent or response lasts &lt;2 hours",
"       </td>",
"       <td>",
"        &lt;40 percent",
"       </td>",
"       <td>",
"        <p>",
"         &lt;25 percent",
"        </p>",
"        <p>",
"         Note: PEF testing may not be needed in very severe attacks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        (on air)",
"       </td>",
"       <td>",
"        Normal (test not usually necessary)",
"       </td>",
"       <td>",
"        &ge;60 mmHg (test not usually necessary)",
"       </td>",
"       <td>",
"        &lt;60 mmHg: possible cyanosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        (on air) and/or PCO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        &lt;42 mmHg (test not usually necessary)",
"       </td>",
"       <td>",
"        &lt;42 mmHg (test not usually necessary)",
"       </td>",
"       <td>",
"        &ge;42 mmHg: possible respiratory failure",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        SpO",
"        <sub>",
"         2",
"        </sub>",
"        percent (on air) at sea level",
"       </td>",
"       <td>",
"        &gt;95 percent (test not usually necessary)",
"       </td>",
"       <td>",
"        90-95 percent (test not usually necessary)",
"       </td>",
"       <td>",
"        &lt;90 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Hypercapnia (hypoventilation) develops more readily in young children than in adults and adolescents.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Notes:",
"    </strong>",
"    <br>",
"     - The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation.",
"     <br>",
"      - Many of these parameters have not been systematically studied, especially as they correlate with each other. Thus, they serve only as general guides (Cham et al. 2002; Chey et al. 1999; Gorelick et al. 2004b; Karras et al. 2000; Kelly et al. 2002b and 2004; Keogh et al. 2001; McCarren et al. 2000; Rodrigo and Rodrigo 1998b; Rodrigo et al. 2004; Smith et al. 2002).",
"      <br>",
"       - The emotional impact of asthma symptoms on the patient and family is variable but must be recognized and addressed and can affect approaches to treatment and followup (Ritz et al. 2000; Strunk and Mrazek 1986; von Leupoldt and Dahme 2005).",
"       <div class=\"footnotes\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        : arterial oxygen pressure; PCO",
"        <sub>",
"         2",
"        </sub>",
"        : partial pressure of carbon dioxide; PEF: peak expiratory flow; SpO",
"        <sub>",
"         2",
"        </sub>",
"        : oxygen saturation.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8718=[""].join("\n");
var outline_f8_32_8718=null;
var title_f8_32_8719="Abdominal aortic aneurysm on ultrasound";
var content_f8_32_8719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Routine sonographic evaluation of an abdominal aortic aneurysm involves measuring the anteroposterior, longitudinal, and transverse dimensions of the aorta. In this instance, the diameters in the transverse dimensions (5.75 and 5.43 cm) are much greater than normal (typically around 2 cm or less). Thrombus or echodense calcifications (arrow) in or adjacent to the aortic wall may also be visualized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emile R Mohler III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_32_8719=[""].join("\n");
var outline_f8_32_8719=null;
